EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[À§³»½Ã°æ ÁúÁöÇ¥. Quality indicators of EGD] - ðû

Previous | Next

2005³â ±¹±º±¤ÁÖº´¿ø ³ëÃæ±¹ º´Àå »ç°ÇÀÄ ÅëÇÏ¿© À§³»½Ã°æ °Ë»ç quality¿¡ ´ëÇÑ Áß´ëÇÑ ¹®Á¦Á¦±â°¡ ÀÖ¾ú½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ¿ì¸®³ª¶ó ³»½Ã°æÀÇ ÁúÇâ»óÀ» À§ÇÑ ¿©Á¤Àº ÇèÇϱ⸸ ÇÕ´Ï´Ù. ±âÃÊ ±³À°µµ Á¦´ë·Î µÇÁö ¾Ê°í ÀÖÀ¸´Ï...

1. À§³»½Ã°æ ÁúÁöÇ¥

2. ¼º¸ðº´¿ø ¹ÚÀç¸í ±³¼ö´ÔÀÇ ³»½Ã°æ ÁúÇâ»ó ¿¬±¸

3. ³»½Ã°æ ÁúÇâ»ó°ú ±³À°ÈÆ·Ã

4. ³»½Ã°æ °Ë»ç °Ç¼ö

5. Missing rate for gastric cancer

6. »õ·Î¿î indicator¿¡ ´ëÇÑ idea

7. [2023-5-8. Çѱ¹°æÁ¦TV] À§³»½Ã°æ ¹Þ¾Ò´Âµ¥ À§¾Ï?¡¦"Àǻ簡 3ºÐ ÀÌ»ó °üÂûÇؾß"

8. Cases

9. FAQs

10. References

2018-12-1. À»Áöº´¿ø ½ÉÆ÷Áö¾ö. ³»½Ã°æ ÁúÁöÇ¥¿¡ ½Ã°£ °³³äÀÌ µé¾î°¡¾ß ÇÑ´Ù°í ÁÖÀåÇÏ¿´½À´Ï´Ù. À§³»½Ã°æÀÇ ÃÖ¼Ò °Ë»ç½Ã°£Àº 5ºÐÀÔ´Ï´Ù.

¿©·¯ ±â°ü¿¡¼­ Á¦½ÃÇÑ ÁúÁöÇ¥¸¦ ¾È¿ëȯ ¿øÀå´Ô²²¼­ Á¤¸® (Å°¸Þµð¿¡¼­ µ¿¿µ»ó º¸±â)


1. À§³»½Ã°æ ÁúÁöÇ¥

2022³â Post-Endoscopy Upper Gastrointestinal Cancers¿¡ ´ëÇÑ Gastroenterology ³í¹®Àº ÀÌ·± ¹®ÀåÀ¸·Î ½ÃÀÛÇÕ´Ï´Ù. ¾î¸¶¾î¸¶ÇÏ°Ô ¸¹ÀÌ ³õÄ¡°í ÀÖ´Ù´Â ¸»ÀÔ´Ï´Ù. ¹°·Ð ÀÌÀ¯°¡ ÀÖ½À´Ï´Ù¸¸...

Ten percent of patients with an upper gastrointestinal cancer will have received an esophagogastroduodenoscopy (EGD) within 3 years before diagnosis, termed post-endoscopy upper gastrointestinal cancers (PEUGIC).

[2017-3-4. ¾Öµ¶ÀÚ Áú¹®]

ÇϺγ»½Ã°æÀÇ Áú Æò°¡ ½Ã »ç¿ëµÇ´Â adenoma detection rate¿Í °°Àº ôµµ°¡ »óºÎ ³»½Ã°æ¿¡µµ Àִ°¡ ÇÏ´Â °ÍÀÔ´Ï´Ù. Á¦ ªÀº ¼Ò°ßÀ¸·Î´Â, ÀÛÀ¸¸é¼­µµ ÀǹÌÀÖ´Â º´¼Ò¸¦ Àß Ã£¾Æ³»´Â ³»½Ã°æ Àǻ簡 ÁÁÀº ³»½Ã°æ Àǻ簡 ¾Æ´Ò±î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. ±×·¡¼­ "ÀǹÌÀÖ´Â ÀÛÀº º´¼Ò¸¦ ãÀº ºñÀ² = ã¾Æ³½ ÀǹÌÀÖ´Â º´¼Ò ¼ö / ³»½Ã°æ ½ÃÇà Ƚ¼ö"·Î Á¤ÀÇÇÒ ±âÁØÀÌ ÀÖ´ÂÁö ¾Ë°í½Í½À´Ï´Ù.

[2017-3-4. ÀÌÁØÇà ´äº¯]

´ëÀå³»½Ã°æ¿¡¼­´Â adenoma detection rate³ª colonoscopy withdrawal time°ú °°Àº À¯¸íÇÑ ÁöÇ¥°¡ ÀÖ½À´Ï´Ù (EndoTODAY 20131117). Colonoscopy withdrawal time°ú adenoma detection rateÀÇ °ü°è´Â ¸í¹éÇÏ°í (Barclay RL. NEJM 2006), adenoma detection rate¿Í interval cancer ¹ß»ý·ü »çÀÌÀÇ ¿¬°ü°ü°èµµ ÀÔÁõµÇ¾ú½À´Ï´Ù (Kaminski MF. NEJM 2010). ±×·¯³ª À§³»½Ã°æ¿¡¼­´Â Á÷°üÀûÀÌ°í ÀÔÁõ°¡´ÉÇÑ À¯¿ëÇÑ ÁúÁöÇ¥°¡ °³¹ßµÇÁö ¾Ê¾Ò½À´Ï´Ù.

ÀÇ·á¿¡¼­ÀÇ ÁúÁöÇ¥´Â (1) structure ÁöÇ¥, (2) process ÁöÇ¥, (3) outcome ÁöÇ¥°¡ ÀÖ½À´Ï´Ù. °¡Àå Á÷°üÀûÀÎ °ÍÀº outcome ÁöÇ¥ÀÌ°í, ´ÙÀ½Àº outcome°ú °ü·Ã¼ºÀÌ ÀÔÁõµÈ process ÁöÇ¥ÀÔ´Ï´Ù. ´ëÀå³»½Ã°æ ¿µ¿ª¿¡´Â outcome ÁöÇ¥ÀÎ adenoma detection rate¿Í outcome°ú °ü·Ã¼ºÀÌ ÀÔÁõµÈ process ÁöÇ¥ÀÎ withdrawal timeÀ̶ó´Â Á÷°üÀûÀÌ°í ½±°Ô ÃøÁ¤ÇÒ ¼ö ÀÖ´Â °ÍµéÀÌ Àֱ⠶§¹®¿¡ ´©±¸³ª µ¿ÀÇÇÏ°í ½±°Ô ¹Þ¾ÆµéÀÏ ¼ö ÀÖ´Â °ÍÀÔ´Ï´Ù. ±×·±µ¥ À§³»½Ã°æ¿¡¼­´Â ±×·± °ÍµéÀÌ ¾ø½À´Ï´Ù.

¿ì¸®³ª¶ó¿¡¼­ ÈçÈ÷ ¾ð±ÞµÇ°í ÀÖ´Â °ÍÀº '±¹°¡¾Ï°ËÁø À§³»½Ã°æ Áú Æò°¡ Ç׸ñ'ÀÔ´Ï´Ù (Â÷Àç¸í. ¼ÒÈ­±â³»½Ã°æ Áú Æò°¡ Ç׸ñ: ¹®Á¦Á¡°ú °³¼± ¹æÇâ). Stucture ÁöÇ¥¿Í process ÁöÇ¥»ÓÀÌ°í outcome ÁöÇ¥´Â ¾ø½À´Ï´Ù.

¿ì¸®³ª¶ó À§³»½Ã°æ ÁúÁöÇ¥

¹Ì±¹³»½Ã°æÇÐȸ¿¡¼­ 2015³â Quality indicators for EGD¸¦ ¹ßÇ¥ÇÑ ¹Ù ÀÖ½À´Ï´Ù. À§³»½Ã°æ¿¡ ´ëÇؼ­´Â 22°³ÀÇ ÁöÇ¥°¡ Á¦½ÃµÇ¾ú´Âµ¥ ¸ù¶¥ process ÁöÇ¥ÀÔ´Ï´Ù (Table 4). Outcome ÁöÇ¥°¡ Çϳªµµ ¾ø¾ú½À´Ï´Ù. 22°³ Áß Áß¿äÇÑ °Í 4°³¸¦ ¼±Á¤ÇÏ¿© µû·Î Á¦½ÃÇÏ¿´´Âµ¥ (Table 5), ¸ðµÎ ±Ë¾ç¿¡ °üÇÑ process ÁöÇ¥¿´½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼­ °ü½ÉÀÖ´Â À§¾Ï °ü·Ã ÁöÇ¥´Â Çϳªµµ ¾ø¾ú½À´Ï´Ù. ±×·¯´Ï À§¾Ï Áø´ÜÀÌ À§³»½Ã°æÀÇ ÃÖ´ë ¸ñÀûÀÎ ¿ì¸® ½ÇÁ¤¿¡´Â ÀüÇô ÀûÇÕÇÏÁö ¾ÊÀº ÁöÇ¥ÀÎ ¼ÀÀÔ´Ï´Ù.

¹Ì±¹ À§³»½Ã°æ ÇÙ½É ÁúÁöÇ¥

À¯·´³»½Ã°æÇÐȸ¿¡¼­µµ 2016³â Performance measures for upper GI ¸¦ ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÌ ¶ÇÇÑ ¸ù¶¥ process ÁöÇ¥¿´½À´Ï´Ù.

À¯·´ À§³»½Ã°æ ÁúÁöÇ¥

Á¦°¡ À¯·´ÀÇ À§³»½Ã°æ ÁúÁöÇ¥¿¡¼­ °ü½ÉÀÖ°Ô º» °ÍÀº ù ³»½Ã°æ °Ë»ç¿Í Àå»óÇÇÈ­»ý ÃßÀû°üÂû¿¡¼­ °Ë»ç½Ã°£(intubation¿¡¼­ extubation±îÁö)ÀÌ 7ºÐÀº µÇ¾î¾ß ÇÑ´Ù´Â °ÍÀ̾ú½À´Ï´Ù ("Percentage of first-time gastroscopies and follow-up gastroscopies for gastric intestinal metaplasia lasting more than seven minutes from intubation to extubation"). ÇöÀç ÀúÀÇ À§³»½Ã°æ °Ë»ç ½Ã°£Àº º¸Åë 4-5ºÐÀÔ´Ï´Ù. À¯·´ ÁúÁöÇ¥ÀÇ Á¤ÀǸ¦ º¸¸é¼­ ¾ÕÀ¸·Î´Â Á¶±Ý ´õ ¿À·¡ °Ë»çÇØ¾ß ÇÏ´ÂÁö °í¹ÎÇÏ°Ô µÇ¾ú½À´Ï´Ù.

Àú´Â ¿ì¸®³ª¶ó¿¡¼­ Á¦¾ÈµÈ ±¹°¡¾Ï°ËÁø À§³»½Ã°æ Áú Æò°¡ Ç׸ñÀÌ ºñ±³Àû Ÿ´çÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù. °Ë»ç½Ã°£ 7ºÐÀº ¿ì¸®³ª¶ó Çö½Ç¿¡¼­ ³Ê¹« ¾î·Á¿î ÀÏÀÔ´Ï´Ù¸¸, 5ºÐ Á¤µµ´Â ÇÊ¿äÇÒ °Í °°½À´Ï´Ù. Adenoma detection rate³ª cancer detection rate´Â ÃøÁ¤Çϸé ÁÁ°ÚÁö¸¸, Æò°¡¸¦ À§ÇÑ ±Ù°Å ÀÚ·á°¡ ¾ø´Ù´Â Á¡ÀÌ ¹®Á¦ÀÔ´Ï´Ù. ¿ì¸®³ª¶ó °ËÁø ³»½Ã°æ¿¡¼­ º¸Åë 300-500¸í °Ë»çÇϸé 1¸í¿¡¼­ À§¾ÏÀÌ ¹ß°ßµÇ°í ÀÖ´Ù´Â Á¡À» °í·ÁÇÏ¿© °¢ÀÚ ½º½º·Î ȤÀº ±â°üÂ÷¿ø¿¡¼­ °Ë»ç °Ç¼ö ´ëºñ À§¾Ï ¹ß°ßÀ²À» ¸ð´ÏÅ͸µÇϸé ÁÁÀ» °Í °°½À´Ï´Ù.

ÁúÇâ»ó ³ë·ÂÀº ¾î·Æ½À´Ï´Ù. William A. Foster´Â ÀÌ·¸°Ô ¸»Çß´Ù°í ÇÕ´Ï´Ù. "Quality is never an accident; it is always the result of high intention, sincere effort, intelligent direction, and skillful execution; it represents the wise choice of many alternatives."


[2017-3-5. °æÈñ´ëÇб³ Â÷Àç¸í ±³¼ö´Ô ÆíÁö]

À§³»½Ã°æ °Ë»ç ½Ã°£¿¡ ´ëÇÏ¿© ÃÖ±Ù ÀϺ»¿¡¼­´Â 7ºÐÀÌ Àû´çÇÑ °Í °°´Ù´Â ÀÇ°ßÀÌ »õ·Ó°Ô Á¦½ÃµÇ¾ú½À´Ï´Ù (Kawamura T. Dig Endosc 2017). ÀÌ ¿¬±¸¿¡¼­´Â Æò±Õ °Ë»ç½Ã°£ÀÌ 6.2ºÐ¿´´Âµ¥, 5ºÐ ¹Ì¸¸À¸·Î °Ë»çÇÏ´Â ÀÇ»çµé¿¡ ºñÇØ 6-7ºÐ °Ë»çÇÏ´Â ÀÇ»ç, 7ºÐ ÀÌ»ó °Ë»çÇÏ´Â ÀÇ»çµéÀÌ À¯ÀÇÇÏ°Ô ´õ ¸¹Àº º´º¯À» ã¾Æ³»°í ÀÖ¾ú½À´Ï´Ù.

Results: Mean examination time of 13 661 EGD without biopsy was 6.2 min (range, 2-18 min). When cut-off times of 5 and 7 min were used, four endoscopists were classified into the fast (mean duration, 4.4 ¡¾ 1.0 min), 12 into the moderate (6.1 ¡¾ 1.4 min), and four into the slow (7.8 ¡¾ 1.9 min) groups. Neoplastic lesion detection rates in the fast, moderate, and slow groups were 0.57% (13/2288), 0.97% (99/10 180), and 0.94% (31/3295), respectively. Compared with that in the fast group, odds ratios for the neoplastic lesion detection rate in the moderate and slow groups were 1.90 (95% confidence interval [CI], 1.06-3.40) and 1.89 (95% CI, 0.98-3.64), respectively.

´ëÀå³»½Ã°æ¿¡¼­ CRC (colorectal cancer)º¸´Ù ADR (adenoma detection rate)À» Ÿ°ÙÀ¸·Î »ï°í ÀÖ´Â °ÍÀº CRC°¡ ¸ñÇ¥ÀÌÁö¸¸, ºóµµ°¡ µå¹°±â ¶§¹®¿¡ ADRÀ» Ÿ°ÙÀ¸·Î »ï´Â °ÍÀÔ´Ï´Ù. À§¾Ï¿¡¼­´Â adenoma-carcinoma¿Í °°ÀÌ ºÐ¸íÇÑ Àü¾Ï¼º º´º¯À» Á¤Çϱ⠾î·Æ±â ¶§¹®¿¡, ADR°ú °°Àº Ÿ°ÙÀ» ¹ß±¼Çϱ⠾î·Æ½À´Ï´Ù. À§ÀÇ adenoma´Â ´ëÀåÀÇ adenoma¿Í ºóµµ¿Í Àǹ̰¡ ÀüÇô ´Ù¸£ ±â ¶§¹®¿¡ À§¿¡¼­ ADRÀ» »ç¿ëÇÒ ¼öµµ ¾ø½À´Ï´Ù.

À§¾Ï ¹ß°ßÀ²º¸´Ù´Â Àü¾Ï¼º º´º¯À» º´¸®ÇÐÀû Áø´Ü ¸ñÇ¥·Î Á¦½ÃÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏÁö¸¸, À§¾ÏÀÇ ¾ÏÈ­ °æ·Î°¡ ´Ù¾çÇÏ°í À§Ã༺ À§¿°À̳ª Àå»óÇÇÈ­»ý º¯È­¸¦ ã¾Æ³»´õ¶óµµ À§¾ÏÀ¸·ÎÀÇ ÁøÇàÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀÌ ¾ø±â ¶§¹®¿¡ ¾î¶² Àü¾Ï¼º º´º¯À» ¸ñÇ¥·Î ¼³Á¤ÇؾßÇÒ Áö ¾Ö¸ÅÇÑ ¸éÀÌ ÀÖ½À´Ï´Ù. ÇâÈÄ ÇØ°áµÇ¾î¾ß ÇÒ Å« ¼÷Á¦ °°Àº ´À³¦ÀÔ´Ï´Ù.


[2017-3-5. ÀÌÁØÇà ´äº¯]

Â÷Àç¸í ±³¼ö´Ô. ÁÁÀº ÀÇ°ß °¨»çÇÕ´Ï´Ù. À§³»½Ã°æ¿¡¼­ adenoma detection rate¸¦ Àû¿ëÇÒ ¼ö ¾ø´Â ÀÌÀ¯¸¦ Àß ¼³¸íÇØ Áּ̽À´Ï´Ù.

À§³»½Ã°æ °Ë»ç ½Ã°£ À̽´´Â Âü ¾î·Æ½À´Ï´Ù. ¹°·Ð ¿À·¡º¸¸é ¿À·¡ º¼¼ö·Ï neoplastic lesionÀ» ¸¹ÀÌ Ã£À» ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. ±×·¯³ª ¹«Á¶°Ç ¸¹Àº °ÍÀÌ ÁÁÀº °ÍÀº ¾Æ´Õ´Ï´Ù.

1) ¸¸¾à ¿À·¡ °üÂûÇÏ¿© Ãß°¡·Î ¹ß°ßµÇ´Â °ÍµéÀÌ ´ëºÎºÐ 2-3mm Àúµµ¼±Á¾À̶ó¸é ²À ±ä °Ë»ç°¡ ÁÁÀº °Ë»ç¶ó°í ¸»ÇÏÁö ¸øÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëÀå¿¡¼­´Â 2-3mm Àúµµ¼±Á¾ÀÌ ¹ß°ßµÇ¸é ±× ÀÚ¸®¿¡¼­ Á¶Á÷°Ë»ç·Î Á¦°ÅÇϱ⠶§¹®¿¡ Ãß°¡ óġ°¡ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù. ÈξÀ ´õ Å« ¼±Á¾µµ one stage polypectomy·Î ±× ÀÚ¸®¿¡¼­ ¹Ù·Î Á¦°ÅÇÕ´Ï´Ù. ±×·¯³ª À§¿¡¼­´Â º´¼ÒÀÇ °æ°è°¡ ¸íÈ®ÇÏÁö ¾Ê°í ÁÖº¯¿¡ ¿°ÁõÀÌ Àֱ⠸¶·ÃÀ̹ǷΠ´ëºÎºÐÀÇ °æ¿ì Á¶Á÷°Ë»ç·Î Á¦°ÅµÇ¾ú´Ù´Â Ç¥ÇöÀ» »ç¿ëÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. À§ ¼±Á¾À» one stage endoscopic resectionÀ» ÇÒ ¼öµµ ¾ø½À´Ï´Ù. µû¶ó¼­ À§ Á¶Á÷°Ë»ç¿¡¼­ neoplastic lesionÀÌ ³ª¿À¸é °ÅÀÇ Ç×»ó ¹º°¡¸¦ ´õ Çؾ߸¸ ÇÏ´Â »óȲ¿¡ óÇÕ´Ï´Ù. ÀÌ¿¡ µû¸¥ ºñ¿ë°ú À§Çèµµ ÇÔ²² °í·ÁµÇ¾î¾ß ÇÕ´Ï´Ù.

2) À§³»½Ã°æÀ¸·Î Áø´ÜµÇÁö ¸øÇÏ¿© ÀÓ»óÀûÀ¸·Î ¹®Á¦°¡ µÇ´Â °ÍÀº º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀ̳ª blind area¿¡ À§Ä¡ÇÑ (ÁøÇ༺) À§¾ÏÀÔ´Ï´Ù. ÀÌ´Â ¿À·¡ º»´Ù°í ã¾ÆÁö´Â °ÍÀÌ ¾Æ´Õ´Ï´Ù. 4-5ºÐÀ̸é ÃæºÐÇÕ´Ï´Ù. °Ë»ç ½Ã°£º¸´Ù´Â Áö½Ä°ú °æÇèÀÌ ºÎÁ·ÇÏ°í ÁÁÀº °Ë»ç ¹æ¹ý("decent endoscopic routine")À» ¹è¿ì°í ÀÍÈ÷Áö ¸øÇÏ¿´±â ¶§¹®ÀÔ´Ï´Ù. ³»½Ã°æ ±³À° ºÎÁ·À» ±ä °Ë»ç½Ã°£À¸·Î ´ëüÇÒ ¼ö ¾ø½À´Ï´Ù. °æÇè°ú Áö½ÄÀÌ ºÎÁ·ÇÑ »óÅ¿¡¼­ Áö³ªÄ¡°Ô ¿À·¡ °Ë»çÇÏ¸é º°´Ù¸¥ ÀÓ»óÀû ÀÇÀÇ°¡ ¾ø´Â º´¼Ò¸¦ ³Ê¹« »ó¼¼È÷ ±â¼úÇÏ°í ºÒÇÊ¿äÇÏ°Ô ¸¹Àº Á¶Á÷°Ë»ç·Î ¿¬°áµÇ¾î ÀÌ»óÇÑ °æ°ú·Î À̾îÁö´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. »ç½Ç ÃæºÐÇÑ ³»½Ã°æ ±³À°À» ¹ÞÁö ¸øÇÑ ºÐµéÀÇ °Ë»ç½Ã°£ÀÌ ´õ ªÀº °æ¿ìµµ ÀÖ½À´Ï´Ù. Àß ¹è¿î ºÐµéÀº ´ë°­ ¾î´À Á¤µµ Àû´çÇÑ ½Ã°£ °Ë»ç¸¦ Çϴµ¥ ¹ÝÇÏ¿©, Àß ¹è¿ìÁö ¸øÇÑ ºÐµéÀº ³Ê¹« ª°Ô Çϰųª ³Ê¹« ±æ°Ô ÇÏ´Â µî Ç¥ÁØÈ­°¡ µÇ¾î ÀÖÁö ¸øÇÕ´Ï´Ù. ¿äÄÁµ¥ ³»½Ã°æ ±³À° À̽´°¡ ´õ Áß¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù.

3) Çö½ÇÀûÀÎ °í·ÁÁ¡µµ ÀÖ½À´Ï´Ù. À§³»½Ã°æÀº ´ëÀå³»½Ã°æ¿¡ ºñÇÏ¿© ´õ ÀÚÁÖ ¹Þ¾Æ¾ß ÇÕ´Ï´Ù. ÁøÁ¤³»½Ã°æÀÌ ¾Æ´Ñ °æ¿ìµµ ¸¹½À´Ï´Ù. °Ë»ç½Ã°£ÀÌ ³Ê¹« ±æ¸é ȯÀÚµéÀÌ ÁöÃļ­ ´ÙÀ½ °Ë»ç¸¦ ²¨·ÁÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. »ç½Ç ¸¹½À´Ï´Ù. Èûµç °Ë»ç ÈÄ "Á×À¸¸é Á×¾úÁö ´Ù½Ã´Â °Ë»ç¹ÞÁö ¾Ê°Ú´Ù"°í ´ÙÁüÇϴ ȯÀÚµµ ÀÖÀ¸´Ï±î¿ä.

¿äÄÁµ¥, À§³»½Ã°æ¿¡¼­µµ °Ë»ç½Ã°£ÀÌ ±æ¸é ¹º°¡ ´õ ¹ß°ßÇÒ ¼ö ÀÖ´Â °ÍÀº »ç½ÇÀÌÁö¸¸ Ç¥ÁØ °Ë»ç ½Ã°£À» Áö³ªÄ¡°Ô ´Ã¸± ±Ù°Å´Â ºÎÁ·ÇÑ °Í °°½À´Ï´Ù. ÃæºÐÇÑ ³»½Ã°æ ±³À°À» ¹ÞÀº ºÐµéÀ̶ó¸é 5ºÐ Á¤µµÀÇ °Ë»ç½Ã°£À̸é acceptableÇÏ´Ù°í »ý°¢µË´Ï´Ù. ȯÀÚÀÇ ±âº» Á¤º¸¸¦ È®ÀÎÇÏ°í, ÁøÁ¤Á¦¸¦ Åõ¾àÇÏ°í, °Ë»ç ±â·ÏÀ» ³²±â´Â °Í±îÁö °í·ÁÇϸé ÇÑ ½Ã°£¿¡ 5¸í Á¤µµÀÇ °Ë»ç°¡ maximumÀÔ´Ï´Ù.

¿ì¸®³ª¶ó¿¡¼­ À§³»½Ã°æ Áú°ü¸®ÀÇ ÇÙ½ÉÀº '³»½Ã°æ ±³À° ÈÆ·Ã'°ú '³»½Ã°æ °Ë»ç ½Ã°£ 5ºÐ'À̶ó°í »ý°¢ÇÕ´Ï´Ù. ÁÁÀº ÀÇ°ß °¨»çÇÕ´Ï´Ù.


[2021-2-25] Endoscopy education conference organized by Pentax

Pentax »çÀÇ ³»½Ã°æ ±³À° webinar¿¡ Âü¼®ÇÏ¿© »ï¼º¼­¿ïº´¿øÀÇ BOXIM ÇÁ·Î±×·¥À» ¼Ò°³ÇÏ¿´½À´Ï´Ù. ¾Æ»êº´¿ø ±èµµÈÆ ±³¼ö´Ô°ú °æºÏ´ë Àü¼º¿ì ±³¼ö´ÔÀÇ ¸ÚÁø °­Àǵµ ÀÖ¾ú½À´Ï´Ù. dz³³µ¿°ú ´ë±¸¿¡¼­ ³»½Ã°æ tutoring ¹æ¹ýÀÌ ±Þ¼ÓÈ÷ ¹ßÀüÇÏ°í ÀÖ´Â ¸ð½ÀÀÌ ÀλóÀûÀ̾ú½À´Ï´Ù.

¾Æ»êº´¿ø ³»½Ã°æ ±³À° ÇÁ·Î±×·¥ Áß À§³»½Ã°æ °Ë»ç ½Ã°£ÀÌ ¾ð±ÞµÈ ºÎºÐÀÌ ÀÖ¾î ¼Ò°³ÇÕ´Ï´Ù. ¾Æ»êº´¿ø¿¡¼­µµ 5ºÐ - 5ºÐ 30ÃÊ °Ë»çÇϵµ·Ï °¡¸£Ä¡°í ÀÖ½À´Ï´Ù. ±×·¸½À´Ï´Ù. À§³»½Ã°æÀº ÃÖ¼ÒÇÑ 5ºÐÀº °Ë»çÇØ¾ß ÇÕ´Ï´Ù. 5ºÐ.

¾Æ»êº´¿ø EGD ÇÁ·Î±×·¥

¾Æ»êº´¿ø EGD method training


2. ¼º¸ðº´¿ø ¹ÚÀç¸í ±³¼ö´ÔÀÇ ³»½Ã°æ ÁúÇâ»ó ¿¬±¸

Longer observation time increases the detection rate of neoplasms in EGC: a quality indicator study °¡Å縯´ëÇб³ ¹ÚÀç¸í (2017-4-8. ÇÑÀÏÇ︮ÄÚ¹ÚÅÍ ÇÐȸ)

A higher neoplasm detection rate was found among endoscopists who had a longer mean examination time during EGD.

[ÀÌÁØÇà ÇѸ¶µð] °ÇÁø À§³»½Ã°æ¿¡¼­ °Ë»ç½Ã°£ÀÌ ±æ¼ö·Ï, Á¶Á÷°Ë»ç¸¦ ¸¹ÀÌ ÇÒ¼ö¸£°í Á¾¾çÀ» ¸¹ÀÌ ¹ß°ßÇÑ´Ù´Â µ¥ÀÌŸÀ̸ç, multivariate analysis¿¡¼­ °Ë»ç ½Ã°£ÀÌ Áß¿äÇÑ quality indicator¿´½À´Ï´Ù. ¸Å¿ì Áß¿äÇÑ ÀÚ·á°¡ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ´Ù¸¸ ¿ì·Á½º·¯¿î °ÍÀº ³Ê¹« ¸¹Àº Á¶Á÷°Ë»çÀÔ´Ï´Ù. ³»½Ã°æ Á¶Á÷°Ë»ç°¡ 6.9-27.8%ÀÇ È¯ÀÚ¿¡¼­ ½ÃÇàµÇ¾ú°í, Á¾¾çÀº 0.14-0.32%¿¡¼­ ¹ß°ßµÇ¾ú½À´Ï´Ù. ´ë°­ 100°³ Á¶Á÷°Ë»ç¿¡¼­ 1°³ Á¾¾çÀÌ ³ª¿Ô´Ù´Â À̾߱âÀÔ´Ï´Ù. ÀúÀÇ ÀÓ»ó °æÇèÀ¸·Î ÆÇ´ÜÇϸé Á¶Á÷°Ë»ç Áß 1%¿¡¼­ Á¾¾çÀÌ ³ª¿Ô´Ù´Â °ÍÀº ³Ê¹« ³·Àº ¼öÄ¡ÀÎ °Í °°½À´Ï´Ù. °ÇÁø À§³»½Ã°æ¿¡¼­ Á¶Á÷°Ë»çÀÇ threshold°¡ ³Ê¹« ³·Àº °ÍÀº ¾Æ´ÑÁö ¿ì·ÁµË´Ï´Ù. ÀÌ ºÎºÐ¿¡ ´ëÇÏ¿© Á» ´õ »ìÆ캼 ÇÊ¿ä°¡ ÀÖÀ» °Í °°½À´Ï´Ù.

ÀÌ ÀÚ·á´Â Gastroenterology 2017³â¿¡ ¹ßÇ¥µÇ¾ú½À´Ï´Ù.


[2019-10-27. ¹ÚÀç¸í ±³¼ö´Ô °­ÀÇ]

¹Ú±³¼ö²²¼­´Â ³»½Ã°æ ½ÃÇàÇÏ´Â ÀÇ»çÀÇ Åµµ¸¦ Áß¿äÇÏ°Ô ¾ð±ÞÇϼ̽À´Ï´Ù. ±Í¹«°¡¼³À̶ó´Â °³³äÀ¸·Î ¼³¸íÇϼ̴µ¥¿ä... "¸ðµç ȯÀÚ¿¡¼­ ¾ÏÀÌ ÀÖ´Ù°í °¡Á¤ÇÏ°í °Ë»ç¸¦ ÇսôÙ. ¾ÏÀÌ ¾øÀ¸¸é ´Ù½Ã °üÂûÇØ¾ß ÇÕ´Ï´Ù."¶ó°í ¸»¾¸ÇϽŠºÎºÐÀº Á¤¸» ¿ÇÀº À̾߱â¶ó°í »ý°¢µÇ¾ú½À´Ï´Ù.

3³âÀ» ±âÁØÀ¸·Î Çß´Ù´Â Á¡ÀÌ ³Ê¹« °¡È¤ÇÑ °Í °°½À´Ï´Ù¸¸... Nat Rev Gastroenterol Hepatol. 2015)

Á¶Á÷°Ë»ç¿Í ¾Ï ¹ß°ßÀ²ÀÇ °ü·Ã¼ºÀº ¿ì¸®³ª¶ó¿Í ¿Ü±¹¿¡¼­ ¸ðµÎ ÀÔÁõµÇ¾ú½À´Ï´Ù.

´ëÀå¿¡¼­ endocytoscopy¸¦ ÀÌ¿ëÇÑ AI°¡ µµ¿òÀÌ µÈ´Ù´Â ½Å¼±ÇÑ ¿¬±¸ÀÔ´Ï´Ù.

Cecum intubation rate¿Í ºñ½ÁÇÑ °ÍÀÌ ampulla of Vater °üÂû·üÀε¥ ampulla of Vater¸¦ ÀÚ¼¼È÷ º» Àǻ簡 ½ÊÀÌÁöÀå°ú À§ Á¾¾ç Áø´ÜÀ²ÀÌ ³ô¾ÆÁý´Ï´Ù.

À§Á¡¸·Àº ÃÖ¼ÒÇÑ 2¹ø ÀÌ»ó º¸µµ·Ï ±ÇÇÏ°í ÀÖ´Ù°í ÇϽʴϴÙ.

º¸´Â °ÍÀÌ ´õ Áß¿äÇÏ°í ¸¹Àº »çÁø ³²±â´Â °Í º¸´Ù ÇÊ¿äÇÑ °Í¸¸Å­ Âï´Â °ÍÀÌ Áß¿äÇÏÁö ¾ÊÀ»±î »ý°¢µË´Ï´Ù.

¹ÚÀç¸í ±³¼ö´ÔÀº °üÂû ½Ã°£ÀÇ Á߿伺¸¦ °­Á¶Çϸ鼭 qaulity improvement¿¡ ´ëÇÑ ¸ÚÁø °­ÀǸ¦ ¸¶Ä¡¼Ì½À´Ï´Ù. °üÂû½Ã°£À» 1ºÐ ´Ã·È´õ´Ï Á¾¾ç Áø´ÜÀ²ÀÌ °ÅÀÇ 50% Áõ°¡µÈ´Ù´Â ¸ÚÁø °æÇèÀ» ¼Ò°³ÇØ Áּ̽À´Ï´Ù.


[2021-12-15] ¹ÚÀç¸í ±³¼ö´Ô °­ÀÇ

¹ÚÀç¸í ±³¼ö´ÔÀÇ °­ÀÇ ³»¿ëÀ» ¾È¿ëȯ ¿øÀå´Ô²²¼­ Á¤¸®

°´°üÀû ÁúÁöÇ¥: (1) ÃæºÐÇÑ ½Ã°£, (2) Protocol, (3) Biopsy rate, (4) ±¸Á¶¹° ÃÔ¿µ

ÁÖ°üÀû ÁúÁöÇ¥: (1) Á¾¾çÀÌ ÀÖ´Ù´Â ±Í¹«°¡¼³·Î °Ë»ç¸¦ ÇÏÀÚ, (2) ¸ÍÁ¡À» ÀνÄÇÏÀÚ, (3) ³ªÀÇ °æÇèÀ» ³Ê¹« ¹ÏÁö ¸»ÀÚ, (4) ³»½Ã°æ ½Ç·ÂÀ» Å°¿ìÀÚ. »öÁ¶ º¯È­¿Í °ø±â ÁÖÀÔ µî

"¸ÅÀÏ °°ÀÌ ÀÌ °æÀüÀ» ¾Ï¼ÛÇÏ´Â ÀÌ¿¡°Ô »ý¸íÀÇ ºûÀÌ ÀÖÀ¸¸®¶ó."


[2022-4-16] SIDDS ¹ÚÀç¸í ±³¼ö´Ô °­ÀÇ]

¿ìÃø ±×·¡ÇÁ¸¦ Àß º¸¸é ÁÁÀ» °Í °°½À´Ï´Ù. Á¶Á÷°Ë»ç¸¦ ¸¹ÀÌÇϸé ÁÖ·Î atrophy³ª metaplasia¿Í °°Àº premalignant conditionÀ» ³ôÀÌÁö¸¸ dysplasia³ª cancer´Â ¾ÆÁÖ Á¶±Ý ´õ ¹ß°ßÇÒ ¼ö ÀÖÀ» »ÓÀÔ´Ï´Ù. Á¶Á÷°Ë»ç¸¦ Çϱâ Àü¿¡ Àß º¸´Â °ÍÀÌ ´õ Áß¿äÇÒÁö ¸ð¸£°Ú½À´Ï´Ù. Á¶Á÷°Ë»ç¸¦ ³Ê¹« ¸¹ÀÌ Çϸé ÇÕº´ÁõÀÌ Áõ°¡µÉ ¼ö ÀÖ°í ³»½Ã°æ½ÇÀ» È¿À²¼ºÀÌ ³·¾ÆÁý´Ï´Ù.


[2022-5] ¹ÚÀç¸í ±³¼ö´Ô review (Clinical Endoscopy 2022³â 5¿ùÈ£)

PDF 0.9M

"To date, no qualified on-site training center exist in Korea."¶ó´Â ºÎºÐÀÌ ¾ÈŸ±î¿ü½À´Ï´Ù. ÇÐȸ¿Í °°Àº °ø½ÄÀûÀÎ ±â°ü¿¡¼­ on-site training center¸¦ ¸¸µé°í ¿î¿µÇϸé ÁÁÀ» °Í °°½À´Ï´Ù. ÇöÀç±îÁö´Â »ï¼º¼­¿ïº´¿ø ÀÓ»ó½Ã¹Ä·¹À̼Ǽ¾ÅÍÀÇ BOXIM programÀ» ÀÌ¿ëÇÏ´Â °ÍÀÌ ÃÖ¼±ÀÌ ¾Æ´Ñ°¡ ½Í½À´Ï´Ù. Covid-19 °ü·ÃÇÏ¿© 2³â °¡·® ÁߴܵǾú´ø BOXIM workshop °ø°³°­Á°¡ 2022³â 6¿ùºÎÅÍ ´Ù½Ã ¿­¸³´Ï´Ù. »ï¼º¼­¿ïº´¿ø ÀÎÅÏ/Àü°øÀÇ/fellow »Ó ¾Æ´Ï¶ó Ÿº´¿ø ÀÎÅÏ/Àü°øÀÇ/fellow/±ºÀÇ°ü/ºÀÁ÷ÀÇ µî ´©±¸³ª Âü¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù (À¯·á). ¿©·¯ºÐÀÇ ¸¹Àº °ü½É°ú Âü¿©¸¦ ºÎŹµå¸³´Ï´Ù. (´ã´çÀÚ)


3. ³»½Ã°æ ÁúÇâ»ó°ú ±³À°ÈÆ·Ã

¿ì¸®³ª¶ó¿¡¼­ 1³â¿¡ ¾ó¸¶³ª ¸¹Àº À§³»½Ã°æÀÌ ½ÃÇàµÇ°í ÀÖÀ»±î¿ä? ÃÖ±Ù ±â»ç¸¦ ¼Ò°³ÇÕ´Ï´Ù.

[2018-5-4. ¸ÞµðÆijª ´º½º] ³»½Ã°æ °Ë»ç ±ÞÁõ¡¦ ³»½Ã°æ½Ç ÀûÁ¤¼ºÆò°¡ ÁøÇàµÈ´Ù

Áö³­ÇØ ¿ä¾ç±Þ¿©ºñ¿ë û±¸°ÇÀ» º¸¸é, »óºÎ¼ÒÈ­±â³»½Ã°æÀº ¾à 344¸¸°Ç, ´ëÀå³»½Ã°æÀº ¾à 211¸¸°Ç¿¡ ´ÞÇß´Ù.

±¹¹Î°Ç°­º¸Çè°ø´Ü °Ç°­°ËÁø Åë°è¿¬º¸¿¡ µû¸£¸é, À§³»½Ã°æÀº 2013³â 472¸¸ 9,407¸í¿¡¼­ 2016³â 604¸¸ 8,812¸íÀ¸·Î 27.9% Áõ°¡Çß´Ù. ´ëÀå³»½Ã°æµµ 2013³â 10¸¸ 3,547¸í¿¡¼­ 2016³â 11¸¸ 7,143¸íÀ¸·Î 13.1% Áõ°¡Çß´Ù.

ÀÌ¿¡ µû¸£¸é ¿ä¾ç±Þ¿©Ã»±¸ À§³»½Ã°æÀÌ 344¸¸ (2017³â), °ø´Ü°ËÁø À§³»½Ã°æÀÌ 604¸¸ (2016³â) Á¤µµ ½ÃÇàµÇ´Â ¸ð¾çÀÔ´Ï´Ù. ÀÌ´Â ¸ðµç °Ë»ç ºñ¿ëÀ» º»ÀÎÀÌ ºÎ´ãÇϱ⠶§¹®¿¡ ¿ä¾ç±Þ¿©°¡ û±¸µÇÁö ¾Ê´Â ´ëÇüº´¿ø °ËÁø¼¾ÅÍÀÇ À§³»½Ã°æÀº Æ÷ÇÔµÇÁö ¾ÊÀº ¼ýÀÚÀÔ´Ï´Ù. ±×·¸´Ù¸é ¿ì¸®³ª¶ó¿¡¼­ 1³â¿¡ À§³»½Ã°æÀÌ 1,000¸¸ °Ç Á¤µµ ½ÃÇàµÇ´Â ¼ÀÀÔ´Ï´Ù. ³î¶øÁö ¾Ê½À´Ï±î? ¸Å³â 1,000¸¸°ÇÀÇ À§³»½Ã°æ °Ë»ç°¡ ½ÃÇàµÇ´Â ³ª¶ó¿¡ Á¦´ë·Î µÈ ³»½Ã°æ training center°¡ Çϳªµµ ¾ø´Ù´Ï ´õ¿í ³î¶øÁö ¾Ê½À´Ï±î?

ÀûÀý¼º Æò°¡°¡ ³»½Ã°æ °Ë»çÀÇ Ç°ÁúÀ» ³ôÀÏ °ÍÀ̶ó°í »ý°¢ÇÏ´Â ºÐµéÀÌ ¸¹½À´Ï´Ù. ±×·² ¼öµµ ÀÖ½À´Ï´Ù. ±×·¯³ª ÀûÀý¼º Æò°¡´Â ÃÖ¼Ò ¼öÁØÀÇ ±âÁØÀ» Á¦½ÃÇÏ´Â °ÍÀÏ »Ó, ¿©Â÷Çϸé ÇÏÇâÆòÁØÈ­¸¦ °¡Á®¿Ã À§Çèµµ ÀÖ½À´Ï´Ù. ÃæºÐÇÑ ÅõÀÚ¿Í Á¦´ë·Î µÈ trainingÀÌ ÇÔ²² ÃßÁøµÇ¾î¾ß ÇÕ´Ï´Ù.

¿À´ÃÀº ÈÞÀÏÀ̾úÁö¸¸, Áý¿¡ ¾î¸°ÀÌ°¡ ¾ø´Â °ü°è·Î º´¿ø¿¡¼­ 6¸íÀÇ ÃʽÉÀÚ¸¦ ´ë»óÀ¸·Î endoscopy box simulator training °³ÀÎ ±³½ÀÀ» ÇÏ¿´½À´Ï´Ù (³»½Ã°æ ±³À°¿¡´Â ¿Õµµ°¡ ÀÖ½À´Ï´Ù. °³Àα³½ÀÀÔ´Ï´Ù). ³»°ú Àü°øÀÇ 3¸í, ³»°ú Àü¹®ÀÇ 1¸í, ¿Ü°ú Àü°øÀÇ 1¸í, ¿Ü°ú Àü¹®ÀÇ 1¸íÀ̾ú½À´Ï´Ù. Èûµé¾úÁö¸¸ º¸¶÷µÈ ½Ã°£À̾ú½À´Ï´Ù. Á¦´ë·Î µÈ ³»½Ã°æ training center¸¦ ¸¸µé¾î º¸°íÀÚ ÇÕ´Ï´Ù.


4. ³»½Ã°æ °Ë»ç °Ç¼ö - ¸¹Àº °Ë»ç¸¦ ÇØ¾ß ÇÏ¸é ³»½Ã°æ °Ë»çÀÇ Ç°ÁúÀ» À¯ÁöÇÒ ¼ö ¾ø½À´Ï´Ù. 1½Ã°£¿¡ 5¸íÀÌ maximumÀÔ´Ï´Ù.

[2019-1-5 µ¥Àϸ® ¸Þµð] ³»½Ã°æ ¾ÈÀüÁöÇ¥ → ½ÃÇà °Ç¼ö ´ëºñ 'Àü¹®Àη¡¯

³»½Ã°æ ÁöÇ¥·Î Àη°ú °Ë»ç °Ç¼ö¶ó´Â °³³äÀÌ Ã³À½À¸·Î Á¦½ÃµÇ¾ú½À´Ï´Ù ([2019-1-5 µ¥Àϸ® ¸Þµð] ³»½Ã°æ ¾ÈÀüÁöÇ¥ → ½ÃÇà °Ç¼ö ´ëºñ 'Àü¹®Àη¡¯). ¸Å¿ì Áß¿äÇÑ º¯È­À̹ǷΠ±â»çÀÇ Àü¹®À» ¿Å±é´Ï´Ù.

³»½Ã°æ °Ë»ç½Ç¸¶´Ù ÀÇ»ç¿Í °£È£»ç´Â 1ÀÎ ÀÌ»ó »óÁÖÇØ¾ß ÇÏ¸ç ½Ã°£ÀÌ ¿À·¡ °É¸®´Â Ä¡·á³»½Ã°æÀÇ °æ¿ì¿¡´Â °£È£Àη 2ÀÎ ÀÌ»óÀÇ ±âÁØÀÌ ÀÖ¾î¾ß ÇÑ´Ù´Â ºÐ¼®ÀÌ ³ª¿Ô´Ù. ³»½Ã°æ½Ç ¾ÈÀü°ü¸®¸¦ À§ÇÑ ±âº»Àû ÁöÇ¥´Ù. ÃÖ±Ù °Ç°­º¸Çè½É»çÆò°¡¿øÀº ´ëÇѼÒÈ­±â³»½Ã°æ¿¬±¸Àç´Ü¿¡ ¡®³»½Ã°æ½Ç ȯÀÚ¾ÈÀü °ü¸®¹æ¾È ¹× Æò°¡±âÁØ °³¹ß¡¯ ¿¬±¸¸¦ ÀÇ·ÚÇß°í ÇöÀç °ü·Ã ³»¿ëÀ» °ËÅä ÁßÀÌ´Ù.

ÀÌ ¿¬±¸°¡ ÁøÇàµÈ ÀÌÀ¯´Â ¸¹Àº ÀÇ·á±â°ü¿¡¼­ °Ë»ç½Ç, ÀÇ·áÀη¿¡ ºñÇØ °úµµÇÏ°Ô ¸¹Àº ³»½Ã°æ°Ë»ç¸¦ ½ÃÇàÇÏ°í ÀÖ´Ù´Â ¹®Á¦°¡ ¹ß»ýÇÏ°í Àֱ⠶§¹®ÀÌ´Ù. ¹°·Ð ³·Àº ³»½Ã°æ ¼ö°¡¿¡ ±âÀÎÇÑ ¹Ù Å©Áö¸¸ ÀÌ·Î ÀÎÇØ ¿ÀÁøÀ²°ú ÇÕº´Áõ ¹ß»ýÀÌ ÇÊ¿¬ÀûÀ¸·Î Áõ°¡ÇÏ°í ÀÖ´Â Ãß¼¼´Ù. ¿¬±¸Àç´ÜÀº ¡°°Ë»ç½Ç, Àη ´ëºñ ÀûÀýÇÑ ³»½Ã°æ °Ë»çÀÇ °Ç¼ö´Â ¾ÈÀüÇÑ È¯°æÀ» À§ÇÑ ±âº»ÀûÀÎ ÁöÇ¥´Ù. ¸¹Àº °Ë»ç¸¦ Çϱâ À§Çؼ­´Â °Ë»ç½Ç, ÀåºñÀÇ È®Ãæ°ú Àη º¸°­ÀÌ ¹Ýµå½Ã ÇÊ¿äÇÏ´Ù¡±°í Áø´ÜÇß´Ù. À̸¦ À§ÇØ °Ë»ç½Ç¸¶´Ù ÀÇ»ç¿Í °£È£»ç´Â 1¸í ÀÌ»ó »óÁÖÇØ¾ß ÇÏ¸ç º¹ÀâÇϰųª ½Ã°£ÀÌ ¿À·¡ °É¸®´Â Ä¡·á³»½Ã°æÀ» ÇÏ´Â µ¿¾È¿¡´Â °£È£ÀηÂÀÌ 2¸í ÀÌ»óÀÌ ±Ù¹«ÇØ¾ß ÇÑ´Ù´Â °á·ÐÀ» ³»·È´Ù. ½ÇÁ¦·Î ³»½Ã°æ½Ç ¹× ȸº¹½Ç Àüü °£È£ÀηÂ, ³»½Ã°æ½Ç °£È£Á¶¹«»ç ¹× º¸Á¶ÀηÂ, ȸº¹½Ç °£È£»ç ¹× º¸Á¶ÀηÂÀº ÇÕº´Áõ ¹ß»ý °¨¼Ò¿¡ À¯ÀÇÇÑ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î È®ÀεƴÙ.

"ȸº¹½ÇÀº °£È£»ç 1¸í´ç ȯÀÚ 10¸íÁ¤µµ ±âÁØ"

ȸº¹½Ç Àüü °£È£Àη 1¸íÀÌ ´Ã¾î³¯¼ö·Ï Ä¡·á °áÀå°æ 1¸¸°Ç ´ç ÇÕº´ÁõÀº 0.131°Ç °¨¼ÒÇÑ °ÍÀ¸·Î Á¶»çµÆ´Ù. Áï, Ä¡·á³»½Ã°æ 1¸¸°Ç ´ç ÇÕº´Áõ 1°ÇÀ» ÁÙÀ̱â À§Çؼ­´Â ȸº¹½Ç Àüü °£È£ÀηÂÀÌ ¾à 8¸í ´Ã¾î³ª¾ß ÇÑ´Ù´Â °ÍÀÌ´Ù.(1/0.131=7.63) Èï¹Ì·Ó°Ôµµ ³»½Ã°æ °Ë»ç½Ç °¹¼ö ¹× ³ÐÀÌ°¡ Áõ°¡ÇÒ¼ö·Ï ÇÕº´Áõ ¹ß»ý ¿ª½Ã Áõ°¡ÇÏ´Â °ÍÀ¸·Î µµÃâµÆ´Ù. ÀÌ´Â ³»½Ã°æ½Ç Å©±â°¡ Å« ±â°ü¿¡¼­ ³­À̵µ ³ôÀº Ä¡·á³»½Ã°æ ½Ã¼úÀÌ ½Ç½ÃµÆÀ» °¡´É¼ºÀ» ¿¹ÃøÇÏ´Â ÁöÇ¥·Î Çؼ®µÈ´Ù. ¿¬±¸Àç´ÜÀº ¡°È¸º¹½Ç Àη ±âÁØÀº ÇöÀç 50%ÀÌ»ó »ó±ÞÁ¾ÇÕº´¿ø¿¡¼­ °£È£»ç 1¸í´ç 10¸í ÀÌ»óÀÇ È¯ÀÚ¸¦ µ¹º¸´Â °ÍÀÌ Çö½ÇÀ̹ǷΠÇâÈÄ ÀÇ¿ø±ÞÀ̳ª º´¿ø±Þ¿¡¼­µµ »óÇâµÈ ±âÁØÀÇ ÀûÀýÇÑ °£È£Àη ȮÃæÀÌ ÇÊ¿äÇÏ´Ù¡±°í ºÐ¼®Çß´Ù. ƯÈ÷ ¡°¾ÈÀüÇÑ ³»½Ã°æ½Ç ȯ°æÀ» ±¸ÃàÇϱâ À§Çؼ­´Â ¾ÈÀü»ç°í¿Í ÇÕº´ÁõÀÇ ¹ß»ýÀ» ºÐ¼®ÇÏ°í Àç¹ßÀ» ¹æÁöÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. À̸¦ À§ÇØ Áö¼ÓÀûÀÎ Æò°¡¿Í ÀûÀýÇÑ ¼ö°¡ÀÇ »êÁ¤Àº ÇʼöÀû¡±À̶ó°í µ¡ºÙ¿´´Ù.

ÇÙ½É ³»¿ëÀ» ºùºù µ¹·Á¼­ ¼³¸íÇÏ°í ÀÖÀ¸¹Ç·Î Á¤È®ÇÑ point¸¦ Àâ±â ¾î·Æ½À´Ï´Ù. ±×·¯³ª ¿äÁ¡Àº ´ÙÀ½°ú °°´Ù°í »ý°¢µË´Ï´Ù. ÇÑ ¸íÀÇ Àǻ簡 ³Ê¹« ¸¹Àº °Ë»ç¸¦ ÇÏ¸é ¾È µÈ´Ù. ³»½Ã°æ °Ë»ç½Ç¿¡ ÇÑ ¸íÀÇ Àǻ簡 »óÁÖÇ϶ó´Â ¸»Àº ¾ç¹æÀ¸·Î °Ë»çÇÏ¸é ¾ÈµÈ´Ù´Â °Í°ú °°Àº ¸»ÀÔ´Ï´Ù. °ÆÁ¤µÇ´Â ºÐµé ¸¹À¸½ÃÁÒ?

"ÇÑ ¸íÀÇ ³»½Ã°æ Àǻ簡 ÇÑ ½Ã°£¿¡ ¸î °ÇÀÇ °Ë»ç¸¦ Çϴ°¡?" ÀÌ°ÍÀÌ °¡Àå ÇÙ½É ÁöÇ¥¶ó°í »ý°¢ÇÕ´Ï´Ù. ÁÁÀº ¸»À̱â´Â Çѵ¥¿ä... À̸¦ Á¤ºÎ¿¡¼­ ¹Þ¾ÆµéÀ̸é Å«ÀÏÀÔ´Ï´Ù. ¼ö°¡¸¦ ¿Ã¸®Áö ¾Ê°í °Ë»ç °Ç¼ö¸¸ Á¦ÇÑÇÏ¸é ±× °á°ú´Â »·Çϴϱî¿ä.

ÀÇ·á´Â ÁøÁöÇØ¾ß ÇÕ´Ï´Ù. °øÀÚ´Ôµµ Áúº´Àº ÁøÁöÇÏ°Ô ¹Þ¾ÆµéÀ̼̽À´Ï´Ù. ÀÇ·á´Â °¡º±°Ô º¼ ÀÏÀÌ ¾Æ´Õ´Ï´Ù. ´Ã ÁøÁöÇÏ°Ô Á¢±ÙÇØ¾ß ÇÕ´Ï´Ù. ÀÇ»ç´Â °Ë»ç¸¦ õõÈ÷ ÇÏ°í (À§³»½Ã°æ 1½Ã°£¿¡ 5°³), Á¤ºÎ´Â ÀûÀýÇÑ ºñ¿ëÀ» Áö±ÞÇØ¾ß ÇÕ´Ï´Ù.

í­ñýá¶ãåðºîúòð - ÒÕåÞ âûì»ø¹ 13.


[´ëÀå³»½Ã°æ Ç°Áú°ú °Ë»ç °Ç¼ö]

¸¹Àº °Ë»ç¸¦ ÇØ¾ß ÇÑ´Ù À§³»½Ã°æ °Ë»çÀÇ Ç°ÁúÀ» À¯ÁöÇÒ ¼ö ¾ø½À´Ï´Ù. ÀÌ´Â ´ëÀå³»½Ã°æ¿¡¼­µµ ¸¶Âù°¡ÁöÀÔ´Ï´Ù. ÀÏÀü¿¡ ´ëÀå³»½Ã°æÀÇ »õ·Î¿î ÁúÁöÇ¥ (1½Ã°£¿¡ ´ëÀå³»½Ã°æ 2¸í ÀÌÇÏ)°¡ Á¦½ÃµÈ ¹Ù ÀÖ½À´Ï´Ù. ¼ö°¡ Àλó ¾øÀÌ´Â ºÒ°¡´ÉÇÑ ÀÏÀÎÁö¶ó Àá½Ã À̾߱âµÇ´Ù°¡ ±Ý¹æ ³íÀÇ°¡ ÁߴܵǾú½À´Ï´Ù. ¾ÈŸ±õ½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼­ Áú ³ôÀº ³»½Ã°æ °Ë»ç¸¦ ÇÒ ¼ö ¾ø´Â °¡Àå Å« ÀÌÀ¯´Â Àú¼ö°¡ÀÔ´Ï´Ù. ½Î±¸·Á ÀÇ·á ¹°·¯³ª¶ó!

2020³â »ï¼º¼­¿ïº´¿ø À§³»½Ã°æ °¡°ÝÇ¥

Á¦°¡ 'ºü¸¥ ³»½Ã°æº¸´Ù ¹Ù¸¥ ³»½Ã°æ'À» ÁÖÀåÇÏ´Â °ÍÀº ¾Æ¹«¸® Á¶½É½º·´°Ô °Ë»çÇÏ´õ¶óµµ ¼Óµµ°¡ ºü¸£¸é °íÇ°Áú ³»½Ã°æÀº ºÒ°¡´ÉÇÏ´Ù°í »ý°¢Çϱ⠶§¹®ÀÔ´Ï´Ù. ÇÑ ¸íÀÇ Àǻ簡 ÇÏ·ç¿¡ ÇÒ ¼ö ÀÖ´Â °Ë»ç ¼ýÀÚ¸¦ ÅëÁ¦ÇÏ´Â °ÍÀÌ ¸ðµç Áú°ü¸®ÀÇ ½ÃÀÛÀÔ´Ï´Ù. À§³»½Ã°æÀº 1 ½Ã°£¿¡ 5¸í, ´ëÀå³»½Ã°æÀº 1½Ã°£¿¡ 2¸í Á¤µµ°¡ maximumÀ̶ó°í »ý°¢ÇÕ´Ï´Ù.

ÃÖ±Ù ´ëÀå³»½Ã°æ °Ë»çÀÇ »õ·Î¿î ÁúÁöÇ¥°¡ Á¦½ÃµÇ¾ú½À´Ï´Ù (½ÉÆò¿ø-À忬±¸ÇÐȸ, ´ëÀå³»½Ã°æ 30ºÐ ÀÌ»ó µî 'ÁöÇ¥' °³¹ß 2018-1-25. µ¥Àϸ®¸Þµð). ÀúÀÇ Æò¼Ò ÁÖÀå°ú ¿Ïº®È÷ ÀÏÄ¡ÇÏ´Â °³³äÀÔ´Ï´Ù¸¸ °ú¿¬ ¿ì¸®³ª¶ó ÀÇ·á Çö½Ç¿¡¼­ Àû¿ëÀÌ °¡´ÉÇÒÁö Àǹ®ÀÔ´Ï´Ù. ±×·¯³ª ¿ì¸®³ª¶ó Á¤Ã¥ ´ç±¹¿¡¼­ ÀÇ»çÀÇ °Ë»ç ¼ýÀÚ¸¦ Á¦ÇÑÇÏ´Â ¹æÇâÀÇ ¿¬±¸¸¦ Áö¿øÇÏ°í ÀÖ´Ù´Â Á¡ÀÌ Áß¿äÇÒ °Í °°½À´Ï´Ù. ÇâÈÄÀÇ Á¤Ã¥ ¹æÇâÀ» ÁüÀÛÄÉÇϱ⠶§¹®ÀÔ´Ï´Ù.

³Ê¹« Áß¿äÇÑ ±â»çÀ̹ǷΠÀü¹®À» ¿Å±é´Ï´Ù.

½ÉÆò¿ø-À忬±¸ÇÐȸ, ´ëÀå³»½Ã°æ 30ºÐ ÀÌ»ó µî 'ÁöÇ¥' °³¹ß 2018-1-25. µ¥Àϸ®¸Þµð

¿ì¸®³ª¶ó ´ëÀå¾Ï ¹ßº´·üÀº ¼¼°è ÃÖ°í ¼öÁØÀÌ´Ù. ¼¼°èº¸°Ç±â±¸(WHO) »êÇÏ ±¹Á¦¾Ï¿¬±¸¼Ò¿¡ µû¸£¸é ±¹³» ´ëÀå¾Ï ¹ßº´·üÀº Àα¸ 10¸¸¸í´ç 45¸íÀ¸·Î Á¶»ç ´ë»ó 184°³±¹ Áß °¡Àå ³ô´Ù. ÀÌ·¯ÇÑ »óȲ ¼Ó ´ëÀåÁ¾¾çÀýÁ¦¿Í °ü·Ã ÀûÁ¤¼ºÆò°¡°¡ ÁغñµÇ°í ÀÖ´Ù. ÁÖ¸ñÇÒ ºÎºÐÀº ³»½Ã°æ ½Ã°£À» ±âÁØÀ¸·Î ÇÑ ÁöÇ¥°¡ ¹ß±¼µÆ´Ù´Â Á¡ÀÌ´Ù. ÃÖ±Ù °Ç°­º¸Çè½É»çÆò°¡¿øÀº ´ëÇÑÀ忬±¸ÇÐȸ¿¡ ÀÇ·ÚÇØ ´ëÀåÁ¾¾çÀýÁ¦ Æò°¡ÁöÇ¥ ¿¬±¸¸¦ ¸¶¹«¸® Áþ°í °ü·Ã ³»¿ëÀ» °ËÅä ÁßÀÌ´Ù. ÀïÁ¡Àº ¡®ÀÏ¹Ý Áø´Ü ´ëÀå³»½Ã°æ 30ºÐ ÀÌ»ó¡¯, ¡®ºÐº¯ÀáÇ÷°Ë»ç ¾ç¼º ÈÄ ´ëÀå³»½Ã°æ 45ºÐ ÀÌ»ó¡¯À̶ó´Â ÁöÇ¥´Ù.

ÀÌ´Â ´ëÀå³»½Ã°æÀº »ðÀÔ, ȸ¼ö ¹× Æú¸³ÀýÁ¦¸¦ À§ÇØ ÇÒ´çµÈ ½Ã°£ÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÌ´Ù. 1ÀÏ ´ëÀå³»½Ã°æ °Ç¼ö°¡ ¸¹¾ÆÁú¼ö·Ï ½ÃÇà ÀÇ»çÀÇ ÇǷεµ°¡ Áõ°¡ÇØ ´ëÀå³»½Ã°æÀÇ Àü¹ÝÀûÀÎ Áú¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. À忬±¸ÇÐȸ´Â ÀûÀýÇÑ ÀÇ»ç 1Àδç 1ÀÏ Æò±Õ ´ëÀå³»½Ã°æ °Ç¼ö Æò°¡ÁöÇ¥ °³¹ßÀ» À§ÇØ ±¹³» 11°³ ´ëÇк´¿ø¿¡¼­ ÀüÇâÀûÀ¸·Î ½ÃÇàÇÑ 1172¸íÀÇ ´ëÀå³»½Ã°æ ÀڷḦ ºÐ¼®Çß´Ù. Æú¸³ÀÌ ¾ø´Â 552°ÇÀÇ ´ëÀå³»½Ã°æ Æò±Õ °Ë»ç½Ã°£Àº 15.9ºÐÀ̾ú°í, Æú¸³ÀÌ ÀÖ´Â 620°ÇÀÇ Æò±Õ °Ë»ç½Ã°£Àº 22.1ºÐÀ̾ú´Ù. ºÐº¯ÀáÇ÷°Ë»ç ¾ç¼ºÀ¸·Î ´ëÀå³»½Ã°æÀ» ½ÃÇàÇÑ 28¸í¿¡¼­ Æò±Õ °Ë»ç½Ã°£Àº 19.5ºÐÀ̾ú´Ù.

ÇÐȸ´Â ¡°Àü óġ ¹× Áغñ½Ã°£À» °í·ÁÇÒ ¶§, ±¹³»¿¡¼­µµ À¯·´ ±âÁØ°ú À¯»çÇÏ°Ô Àû¿ëÇÒ ÇÊ¿ä°¡ ÀÖÀ¸¹Ç·Î 30ºÐ, 45ºÐ ±âÁØÀ» ÁØ¿ëÇÒ ÇÊ¿ä°¡ ÀÖ´Ù. ȯÀÚ Áø·áÀÇ ÁúÀ» Çâ»ó½ÃÅ°°í ´Ù¾çÇÑ ½Ã°¢¿¡¼­ ȯÀÚ¸¦ °í·ÁÇÏ´Â ±âȸ°¡ Áõ°¡ÇÏ´Â µî ±àÁ¤Àû ¿µÇâÀ» ¹ÌÄ¥ °Í¡±À̶ó°í ¹àÇû´Ù. ´Ù¸¸ ÀÀ±Þ ´ëÀå³»½Ã°æ, °èȹµÈ Æú¸³ÀýÁ¦¼ú, ¼ö¼ú Àü À§Ä¡ È®ÀÎÀ» À§ÇÑ °Ë»ç, ´ëÀåÀýÁ¦¼ú ÈÄ ÃßÀû°Ë»ç´Â Á¦¿ÜÇϱâ·Î Çß´Ù.

À̸¦ ÇÐȸ ¼Ò¼Ó 19¸íÀÇ Àü¹®°¡µé¿¡°Ô ÀÇ°ßÀ» ±¸ÇÑ °á°ú, 36.8%¸¸ µ¿ÀÇÇÑ´Ù´Â ÀÔÀåÀÌ ³ª¿Ô´Ù. Æò°¡ ½Ã ÇÊ¿äÇÑ ºÎºÐÀ̱ä ÇÏÁö¸¸ ÁöÇ¥ µµÀÔ ½Ã ´Ù¼Ò ºÎ´ã½º·¯¿î ºÎºÐÀ̶ó´Â Çؼ®À¸·Î Ç®À̵ȴÙ. ¹Ý¸é ¡®±â°ü´ç Àü¹®ÀÇ 1ÀÎ È®º¸¡¯ 94.7%, ³»½Ã°æ Àåºñ º¸À¯ ¡®100%¡¯, º¸Á¶Àη 1ÀÎ º¸À¯ ¡®100%¡¯ µî ±âŸ ±¸Á¶ ÁöÇ¥¿¡¼­´Â ´ëüÀûÀ¸·Î ÇÕÀÇ ¼öÁØÀÌ ³ô¾Ò´Ù. ÃßÈÄ Æò°¡ ÁøÇà ½Ã ¿ì¼± µµÀÔÇÒ Ç׸ñÀÌ µÉ °ÍÀ¸·Î °üÃøµÈ´Ù. Æò°¡ÁöÇ¥ °³¹ß°ú °ü·Ã, ½ÉÆò¿ø °ü°èÀÚ´Â ¡°´ëÀåÁ¾¾çÀýÁ¦¼ú Æò°¡ÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ´Â »óȲÀÌ°í ±× Ã¹ ´Ü°è·Î ÁöÇ¥°³¹ßÀÌ ÀÌ·ïÁ³´Ù. ÇÏÁö¸¸ ¿ÃÇØ ´çÀå ÃßÁøÇϱâ´Â ¾î·Æ°í ÃßÈÄ ¿©·¯ °ËÅä¿Í ³íÀǸ¦ ÅëÇØ Æò°¡ ½Å¼³ µî °áÁ¤ÀÌ ÀÌ·ïÁú °Í¡±À̶ó°í ¹àÇû´Ù.


6. Missing rate for gastric cancer

À§³»½Ã°æ¿¡¼­ À§¾ÏÀ» ³õÄ¡´Â °æ¿ì´Â ¾î´À Á¤µµÀϱî¿ä?

À§¾Ï miss rate¸¦ Æò°¡ÇÏ´Â ¿¬±¸¹æ¹ýÀÌ ¸ðµÎ ´Þ¶ó¼­ ÇϳªÀÇ ´äÀ» ³»±â´Â ¾î·Æ½À´Ï´Ù. 2016³â ÀÌ ÁÖÁ¦¿¡ ´ëÇÑ ¸ÞŸºÐ¼®À» Âü°íÇÏ´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù. ¾à 10%¶ó°í ÇÕ´Ï´Ù. À§¾Ï 10°³ Áß Çϳª´Â ³õÄ£´Ù°í »ý°¢ÇÏ´Â °ÍÀÌ ÇÕ¸®ÀûÀÏ °Í °°½À´Ï´Ù (Eur J Gastroenterol Hepatol 2016). °â¼ÕÇÏ°í ¶Ç °â¼ÕÇÒ ¼ö ¹Û¿¡...

Results: The studies included (n=22) were grouped by study design. The pooled negative predictive value was 99.7% (95% confidence interval 99.6-99.9%). Missed GCs proportion was 9.4% (95% confidence interval 5.7-13.1%), being 10.0% in studies including patients with negative EGD followed over time, 8.3% in studies including patients with GC, and 23.3% in studies evaluating the proportion of missed synchronous lesions. Mainly, missed cancers were located in the gastric body both in Eastern and in Western studies (39 and 47%, respectively). The majority of missed GCs were adenocarcinomas. Younger age (<55 years), female sex, marked gastric atrophy, gastric adenoma or ulcer, and inadequate number of biopsy fragments were reported as predictive factors for diagnostic failure.

Conclusion: EGD is a very effective method to rule out GC. However, missing GC with EGD is not uncommon, with one out of 10 cancers being potentially missed. Interestingly, lesions were more often missed in the body and therefore a more rigorous protocol for endoscopy and biopsy should be implemented worldwide.


6. »õ·Î¿î indicator¿¡ ´ëÇÑ idea

[À§°Ô½Ç]

Âü°í¹®ÇåÀ» ãÀ» ¼ö ¾ø½À´Ï´Ù¸¸, À§°Ô½ÇÀÇ ¹ß°ßÀ²À» À§³»½Ã°æ °Ë»çÀÇ ÁúÁöÇ¥·Î »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â ³í¹®À» º» ÀûÀÌ ÀÖ½À´Ï´Ù. À§°Ô½Ç ÀÚü°¡ ¹«½¼ Áß¿äÇÑ Àǹ̰¡ ÀÖ´Â °ÍÀº ¾Æ´ÏÁö¸¸ À§°Ô½ÇÀ» Àß ¹ß°ßÇÒ Á¤µµ·Î ±¸¼®±îÁö Á¤¼º²¯ »ìÆñ´Ù¸é ÈǸ¢ÇÑ °Ë»ç¶ó´Â ÀǹÌÀÏ °ÍÀÔ´Ï´Ù.

50´ë ³²¼ºÀÔ´Ï´Ù. À§°Ô½ÇÀ» ¹ß°ßÇÏ¿´½À´Ï´Ù.

±×·±µ¥ ȯÀÚ°¡ 6°³¿ù Àü ³»½Ã°æ °Ë»ç¸¦ ¹Þ¾Ò´Ù°í ÇÏ´õ±º¿ä. ±×·¡¼­ °ú°Å »çÁøÀ» »ìÆ캸¾Ò½À´Ï´Ù.

ÀüÁ¤ºÎ°¡ ù »çÁøÀ̶ó Á¤È®È÷ °Ë»ç ½Ã°£À» ÃøÁ¤ÇÒ ¼ö ¾ø¾úÁö¸¸, ù »çÁøÀº 10½Ã 20ºÐ 1ÃÊÀÌ°í ¸¶Áö¸· »çÁøÀº 10½Ã 20ºÐ 46ÃÊ¿´½À´Ï´Ù. ´ëºÎºÐ »çÁøÀÌ Èçµé¸®°Å³ª È帰 »óÅ¿´´Âµ¥ contrast enhancement´Â A1À¸·Î µÇ¾î ÀÖ¾ú½À´Ï´Ù. ³Ê¹«ÇÏ¿´´Ù´Â »ý°¢ÀÔ´Ï´Ù.

ºü¸¥ ³»½Ã°æº¸´Ù ¹Ù¸¥ ³»½Ã°æÀ» ÇսôÙ. »óºÎ³»½Ã°æ °Ë»çÀÇ ÃÖ¼Ò °Ë»ç ½Ã°£Àº 5ºÐÀÔ´Ï´Ù.


[Case]

2014³â ȯÀÚÀÔ´Ï´Ù. ±×¶§±îÁö¸¸ Çصµ ³»½Ã°æÀ» »¡¸® ÇÏ´Â ÀÇ»çµéÀÌ ¸¹¾Ò½À´Ï´Ù. ±×·¯³ª ÇöÀç´Â 'À§³»½Ã°æ °Ë»ç ½Ã°£Àº ÃÖ¼ÒÇÑ 5ºÐ'ÀÌ °ÅÀÇ standard°¡ µÇ¾ú½À´Ï´Ù. (Àú¸¸ÀÇ Âø°¢Àϱî¿ä?)

³»½Ã°æ °Ë»ç ½Ã°£ÀÌ Âª¾Ò´ø ½ÃÀý¿¡´Â ¾ÈŸ±î¿î »ç¿¬ÀÌ ¸¹¾Ò½À´Ï´Ù. 2013³â ȯÀÚÀε¥ 50´ë ³²¼ºÀ̼̽À´Ï´Ù. º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀÌ°í ÀÌ¹Ì º¹¼ö±îÁö ¹ß»ýµÈ »óȲÀ̾ú°í palliative chemotherapy¹Û¿¡ ÇÒ ¼ö ¾ø¾ú½À´Ï´Ù. ±×·±µ¥, ȯÀÚ´Â 8°³¿ù Àü¿¡ ³»½Ã°æ °Ë»ç¸¦ ¹ÞÀ¸¼Ì´Ù°í Çϼ̽À´Ï´Ù. ±× ¶§ »çÁøÀ» »ìÆ캸´Ï... ¾Æ»Ô»ç... À§³»½Ã°æ °Ë»ç ½Ã°£ÀÌ 2ºÐµµ µÇÁö ¾Ê¾Ò½À´Ï´Ù. »çÁøÀº 23Àå ÀÖ¾úÁö¸¸ À§Ã¼ÇϺÎÀÇ ÁÖ¸§ÀÌ Àß ³ª¿Àµµ·Ï °ø±â¸¦ ÃæºÐÈ÷ ³ÖÀº »óÅÂÀÇ »çÁøÀº ¾ø¾ú½À´Ï´Ù. ±×³ª¸¶ À§ ÁÖ¸§ÀÌ ÂïÈù ¸î ÀåÀÇ »çÁøÀ» ÈÄÇâÀûÀ¸·Î »ìÆ캸¾Ò´Âµ¥... Á¤»óÀº ¾Æ´Ï¾ú½À´Ï´Ù. °æÇ踹Àº Àǻ簡 õõÈ÷ °Ë»çÇÏ¿´´Ù¸é ÃæºÐÈ÷ Áø´ÜÇÒ ¼ö ÀÖ´Â »óȲÀ̾ú´Ù°í ÃßÁ¤µÇ¾ú½À´Ï´Ù.

±×·¸½À´Ï´Ù. 2ºÐÂ¥¸® °Ë»ç¶ó¸é... ±× ¸¹Àº ÁúÁöÇ¥°¡ ´Ù ¼Ò¿ë¾ø´Â ÀÏÀÔ´Ï´Ù. »çÁø ¸¹ÀÌ Âï´Â´Ù°í °Ë»ç Àß ÇÑ °Í ¾Æ´Õ´Ï´Ù. õõÈ÷ ÀÚ¼¼È÷ º¸´Â °ÍÀÌ ÁÁÀº °Ë»çÀÔ´Ï´Ù. 'À§³»½Ã°æ °Ë»ç´Â ÃÖ¼ÒÇÑ 5ºÐ'À̶ó´Â ÀÌ ´Ü¼øÇÑ ¿øÄ¢À» ²À ÁöÅ°µµ·Ï ÇսôÙ.

¿ä¾àÇÕ´Ï´Ù. ºü¸¥ °Ë»ç´Â ÈÄÁø °Ë»çÀÔ´Ï´Ù. 'ºü¸¥ ³»½Ã°æº¸´Ù ¹Ù¸¥ ³»½Ã°æ'À» À§ÇØ ³ë·ÂÇսôÙ.


[More cases]

½ÊÀÌÁöÀå 33:33, À§¾Ï ¹ß°ß 34:06, Á¶Á÷°Ë»ç 34:48, »óºÎ½Äµµ 35:26. 2ºÐµµ ¾ÈµÇ´Â ³»½Ã°æ µ¿¾È À§¾Ïµµ ¹ß°ßÇÏ°í Á¶Á÷°Ë»ç¸¦ ÇßÀ¸´Ï °¨ÅºÀÌ¶óµµ ÇØ¾ß ÇÏ´Â °ÍÀϱî¿ä?


[FAQ]

[2019-8-17. ¼ÓÆíÇѳ»°ú ½ÉÆ÷Áö¾ö Âü¼®ÀÚ Áú¹®]

ÃÖ±Ù ³»½Ã°æ¿¡¼­ miss µÇ¾ú´ø ÁøÇ༺ À§¾Ï ȯÀÚ Áõ·Ê°¡ ½Ã»çÇÏ´Â ¹Ù Å©´Ù°í »ý°¢ÇÕ´Ï´Ù.

Çö½ÇÀûÀ¸·Î »óºÎÀ§Àå°ü Áõ¼¼·Î ³»¿øÇÑ È¯ÀÚ°¡ ºÒ°ú ¾ó¸¶ Àü¿¡ ŸÀÇ·á±â°ü¿¡¼­ ³»½Ã°æ °Ë»ç¸¦ ¹Þ¾Ò°í º° ÀÌ»óÀÌ ¾ø´Ù°í µé¾úÀ¸¸é Àç°ËÀ» ÇÒ ¼öµµ ¾ø°í ¾È ÇÒ ¼öµµ ¾ø´Â »óȲÀÌ µË´Ï´Ù. ¼±»ý´ÔÀº ¾î¶² ±âÁØÀ¸·Î Àç°Ë ¿©ºÎ¸¦ °áÁ¤ÇϽʴϱî?

[2019-8-17. ÀÌÁØÇà ´äº¯]

¸Å¿ì ¾î·Á¿î Áú¹®ÀÔ´Ï´Ù. ÇÑ ¸¶µð·Î '°Ë»ç ½Ã°£'ÀÔ´Ï´Ù.

À§¾ÏÀ» ³õÄ¡Áö ¾Ê±â À§Çؼ­ ³»½Ã°æ ÀÇ»çÀÇ ½Ç·Â°ú ÃæºÐÇÑ °Ë»ç ½Ã°£ÀÌ Áß¿äÇÕ´Ï´Ù. ½Ç·Â¾ø´Â ÀÇ»ç´Â º´À» º¸°íµµ Áø´ÜÇÏÁö ¸øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃæºÐÇÑ training°ú ¸¹Àº ÀÓ»ó°æÇèÀÌ Áß¿äÇÕ´Ï´Ù. ¿©±â±îÁö´Â ³Ê¹« ´ç¿¬ÇÑ À̾߱âÀÔ´Ï´Ù.

¹®Á¦´Â '¾î´À Á¤µµ°¡ ÃæºÐÇÑ °Ë»ç ½Ã°£Àΰ¡?'ÀÔ´Ï´Ù. ¾Æ·¡ ¼­¿ï¼º¸ðº´¿øÀÇ ÀڷḦ º¸´õ¶óµµ °üÂû½Ã°£ 4ºÐ (¿¬±¸¿¡¼­´Â ½ÊÀÌÁöÀåÀ¸·ÎºÎÅÍ ³ª¿À´Â ½Ã°£¸¸ °è»êÇÏ¿© 3ºÐÀ» ±âºÐÀ¸·Î ³ª´©¾ú½À´Ï´Ù¸¸, µé¾î°¡´Â ½Ã°£À» °í·ÁÇÏ¸é ½ÇÁ¦·Î´Â 4ºÐÀÌ ±âÁØÁ¡ÀÔ´Ï´Ù) ¹Ì¸¸¿¡¼­´Â Á¾¾ç¼º ÁúȯÀÇ Áø´ÜÀ²ÀÌ ¾öû ¶³¾îÁý´Ï´Ù.

À¯·´¿¡¼­´Â À§³»½Ã°æ °Ë»ç½Ã°£ 7ºÐÀ» Áß¿äÇÑ ÁúÁöÇ¥·Î Á¦½ÃÇÏ°í ÀÖ½À´Ï´Ù.

Àú´Â ¿ì¸®³ª¶ó ȯ°æ¿¡¼­ À§³»½Ã°æ °Ë»ç½Ã°£Àº ÃÖ¼ÒÇÑ 5ºÐÀº µÇ¾î¾ß ÇÑ´Ù°í ÁÖÀåÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ·¡ µ¿¿µ»óÀ» º¸½Ã±â ¹Ù¶ø´Ï´Ù. Box simulator·Î (1) °ø±â¸¦ ³ÖÁöµµ ¾Ê°í, (2) ħÀ» suctionÇÏÁö ¾Ê°í, (3) »çÁøµµ ÂïÁö ¾Ê°í, (4) µÎ¸®¹ø °Å¸®Áö ¾Ê°í ±×³É ½Äµµ¿Í À§¿¡ µé¾î°¬´Ù ³ª¿À´Âµ¥ 1ºÐ 20ÃÊ°¡ °É·È½À´Ï´Ù. °ø±âµµ ³Ö°í ħµµ suctionÇÏ°í »çÁøµµ ÂïÀ¸¸é¼­ µÎ¸®¹ø µÎ¸®¹ø °ñ°í·ç ½ÊÀÌÁöÀå±îÁö »ìÇÇ·Á¸é ÃÖ¼ÒÇÑ 5ºÐÀº ÇÊ¿äÇÕ´Ï´Ù.

Pentax endoscope + new simulator

¾î¶² ¼±»ý´Ô²²¼­´Â "Àü º´¿ø¿¡¼­ ´©°¡ °Ë»ç¸¦ Çߴ°¡¸¦ º¸°í ÆÇ´ÜÇÑ´Ù"¶ó°í ¸»¾¸Çϼ̴µ¥ ¾î´À Á¤µµ Ÿ´ç¼ºÀº ÀÖ½À´Ï´Ù. ±×·¯³ª ´©°¡ ³»½Ã°æÀ» Çß´ÂÁö ¾Ë±â ¾î·Á¿î °æ¿ìµµ ¸¹À» »Ó´õ·¯, ¼³È¤ °æÇèÀÌ ¸¹Àº »ç¶÷ÀÌ °Ë»ç¸¦ Çß´õ¶óµµ Áúº´À» ³õÄ¡Áö ¸»¶ó´Â ¹ýÀÌ ¾ø½À´Ï´Ù. Àú´Â ³»½Ã°æ ÀÇ»çÀÇ ½Ç·Â ¸øÁö ¾Ê°Ô ³»½Ã°æ °Ë»ç ½Ã°£À» Áß¿äÇÏ°Ô »ý°¢ÇÕ´Ï´Ù. Screening setting¿¡¼­´Â °Ë»ç ½Ã°£ÀÌ ´õ Áß¿äÇÕ´Ï´Ù. Àü º´¿øÀÇ ³»½Ã°æ °Ë»ç ½Ã°£ÀÌ 4-5ºÐµµ µÇÁö ¾ÊÀ¸¸é Àç°ËÀ» ±ÇÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¾Æ¹«¸® °æÇè ¸¹Àº Àǻ簡 °Ë»çÇß´õ¶óµµ °Ë»ç ½Ã°£ÀÌ Âª´Ù¸é ÁÁÀº °Ë»ç¸¦ ¹Þ¾Ò´Ù°í ¸»Çϱ⠾î·Æ½À´Ï´Ù.

»çÁøÀÇ ¸¹°í ÀûÀ½Àº ³»½Ã°æ °Ë»çÀÇ Áú°ú ¾Æ¹«·± »ó°üÀÌ ¾ø½À´Ï´Ù. ¾Æ·¡ ȯÀÚ´Â À§¾ÏÀÌ µÎ°³¿´´Âµ¥ À§Ã¼ÇϺΠÀüº®ÀÇ ¾ÏÀº ù °üÂû(³ë¶õ»ö box)¿¡¼­ ¹ß°ßµÇÁö ¾Ê¾Ò´Ù°¡ À§Ã¼Áß»óºÎ ¾ÏÀ» ¹ß°ßÇÑ ÀÌÈÄ¿¡ °ø±â¸¦ ¸¹ÀÌ ³Ö°í °Ë»çÇÏ´Â °úÁ¤¿¡¼­ µÚ´Ê°Ô ¹ß°ßµÇ¾ú½À´Ï´Ù.

¿À´Ã ½Ä»ç Áß ¾î¶² ¼±»ý´Ô²²¼­ ÀÌ·± ¸»¾¸À» Çϼ̽À´Ï´Ù. "Â÷¶ó¸® °ú°Å Æú¶ó·ÎÀ̵å·Î »çÁø 4Àå Âï¾úÀ» ¶§ ´õ ÀÚ¼¼È÷ °üÂûÇß´ø °Í °°´Ù. ¸¹Àº »çÁøÀ» Âï´Â °Í ÀÚü°¡ °Ë»ç¿¡ ¹æÇØ°¡ µÉ ¼ö ÀÖ´Ù." ÀüÀûÀ¸·Î µ¿ÀÇÇÕ´Ï´Ù. À§³»½Ã°æÀ̳ª ´ëÀå³»½Ã°æÀ̳ª »çÁø 15ÀåÀ̸é ÃæºÐÇÕ´Ï´Ù. ±× ÀÌ»óÀº noiseÀÔ´Ï´Ù. ÀÚ¼¼È÷ º¸´Â °ÍÀÌ Áß¿äÇÏÁö »çÁøÀÇ ¼ö°¡ Áß¿äÇÏÁö ¾Ê½À´Ï´Ù.

ÁøÁ¤(¼ö¸é)³»½Ã°æµµ °Ë»çÀÇ Á¤È®µµ°¡ ³·À» ¼ö ÀÖ½À´Ï´Ù. Procedural sedation ¼öÁØ-ȯÀÚ°¡ ÀáÀÚÁö ¾ÊÀ» Á¤µµ-À¸·Î ¾ÆÁÖ ¾àÇÏ°Ô sedationÀ» Çϸ鼭 °Ë»çÇÏ´Â °ÍÀÌ ¿øÄ¢ÀÔ´Ï´Ù. ÀÌ·¸°Ô Çϸé Áø´ÜÀÇ Á¤È®µµ¿¡´Â ¾Æ¹«·± ¹®Á¦°¡ ¾ø½À´Ï´Ù. ±×·±µ¥ ¿ì¸®³ª¶ó¿¡¼­´Â ¼­±¸¿¡¼­ ±ÇÇÏ´Â ¿ë·®º¸´Ù 2¹è ÀÌ»ó ¸¹Àº ¾àÀ» »ç¿ëÇÏ¿© Ç« Àç¿ì´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±× °úÁ¤¿¡¼­ paradoxical responseµµ ¸¹°í, ȯÀÚÀÇ ÇùÁ¶°¡ Àß µÇÁö ¾Ê¾Æ ÃæºÐÈ÷ °Ë»çÇÏÁö ¸øÇÏ´Â ¿¹°¡ ÀûÁö ¾ÊÀº °Í °°½À´Ï´Ù. PropofolÀ» ¾²¸é °Ë»ç µµÁß È¯ÀÚ°¡ ±ú´Â °æ¿ì°¡ À־ ´õ º¸°í ½Í¾îµµ ±×³É ³ª¿À´Â °æ¿ìµµ ÀÖ´Ù°í µé¾ú½À´Ï´Ù.

°Ë»ç ½Ã°£ÀÌ ¾ÆÁÖ ÂªÀº °Ë»ç´Â ´ëºÎºÐ ÁøÁ¤(¼ö¸é)³»½Ã°æÀ̾ú´ø °Í °°½À´Ï´Ù. ¸ÇÁ¤½ÅÀ¸·Î °Ë»ç¸¦ Çϸ鼭 °Ë»ç½Ã°£ÀÌ ¾ÆÁÖ ÂªÀ¸¸é ȯÀڷκÎÅÍ "Á¦´ë·Î º» °ÍÀ̳Ä?" Ç×Àǹޱ⠸¶·ÃÀ̹ǷΠÁ¶±Ý õõÈ÷ ÀÚ¼¼È÷ º¸Áö ¾ÊÀ» ¼ö ¾ø½À´Ï´Ù. ¹°·Ð ÇùÁ¶°¡ ¾È µÇ¾î °Ë»ç ÀÚü°¡ ¾î·Á¿î °æ¿ìµµ ÀÖÁö¸¸... ¿©ÇÏÆ° ¼ö¸éÀÌ³Ä ¾Æ´Ï³Ä´Â Áß¿äÇÏÁö ¾Ê½À´Ï´Ù. Àß º¸´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. Àß º¸´Â °ÍÀÇ °¡Àå Áß¿äÇÑ Á¶°ÇÀº ±æ°Ô º¸´Â °ÍÀÔ´Ï´Ù. ¿À·¡ ºÁ¾ß ¾ÏÀ» ³õÄ¡Áö ¾Ê½À´Ï´Ù. ÃÖ¼ÒÇÑ 5ºÐÀÔ´Ï´Ù. Æò±Õ °Ë»ç ½Ã°£ÀÌ 5ºÐÀº µÇ¾î¾ß Á¤»óÀÔ´Ï´Ù.

ÇѸ¶µð·Î ¿ä¾àÇÕ´Ï´Ù. Àú´Â ª°Ô °Ë»ç¹Þ°í ¿À½Å ºÐÀº °Ë»ç ¾È ÇϽŠ°ÍÀ¸·Î Ä¡°í Àç°ËÀ» ±ÇÇÏ°í ÀÖ½À´Ï´Ù. ºü¸¥ ³»½Ã°æº¸´Ù ¹Ù¸¥ ³»½Ã°æÀ» ÇսôÙ.


[2020-4-8] ³»½Ã°æ °Ë»ç·á

¿ì¿¬È÷ ³»½Ã°æ °Ë»ç °¡°ÝÇ¥¸¦ º¸¾Ò½À´Ï´Ù. ÀÌ °¡°ÝÀ¸·Î Áú°ü¸®¸¦ Ç϶ó´Ï ÀÔÀÌ ´Ù¹°¾îÁöÁö ¾Ê½À´Ï´Ù. ±×·¯³ª ÇÏÁö ¾ÊÀ» ¼öµµ ¾ø½À´Ï´Ù. °Ë»ç¿¡µµ ÀûÀýÇÑ °¡°ÝÀÌ ÇÊ¿äÇÕ´Ï´Ù.

2020³â À§³»½Ã°æ °¡°ÝÇ¥


[2020-12-15] ³»½Ã°æÇÐȸ Áú°ü¸® À§¿øȸ on-line °øûȸ

³»½Ã°æÇÐȸ Áú°ü¸® À§¿øȸ on-line °øûȸ¿¡¼­ screenshotÀÔ´Ï´Ù. ÅëÇÕ 4Áֱ⠱¹°¡¾Ï°ËÁø ³»½Ã°æ °á°úÁö¿¡ 'À§³»½Ã°æ ½Ã¼ú½Ã°£' Ãß°¡¸¦ °í·ÁÇØ¾ß ÇÑ´Ù´Â Á¦¾ÈÀÔ´Ï´Ù. Á¤¸» ȹ±âÀûÀÎ ¾ÆÀ̵ð¾î¶ó°í »ý°¢ÇÕ´Ï´Ù. 100¹ø 1000¹ø Âù¼ºÇÕ´Ï´Ù. ³»½Ã°æÀÌ ÀÔ¿¡ µé¾î°¡´Â ¼ø°£ºÎÅÍ ÀÔ¿¡¼­ ³ª¿Ã ¶§±îÁö ÃÖ¼ÒÇÑ 5ºÐÀº ÇÊ¿äÇÕ´Ï´Ù. ±×°Ô minimumÀÔ´Ï´Ù.

ÁúÁöÇ¥°¡ ¸¹´Ù°í ÁúÀÌ ÁÁ¾ÆÁö´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ÁúÁöÇ¥´Â ÁúÀÌ ÁÁ¾ÆÁö´Â ¹æÇâÀ¸·Î ¸¸µé¾îÁ®¾ß ÇÕ´Ï´Ù. ÁöÇ¥¸¦ Àß ¸ø ¸¸µé¸é ÁúÁöÇ¥¸¸ ÁÁ¾ÆÁö°í ½ÇÁ¦ÀûÀÎ Áú(òõ)Àº ³ªºüÁý´Ï´Ù. ³»½Ã°æ ÁúÁöÇ¥·Î °¡Àå Áß¿äÇÑ µÎ °¡Áö´Â (1) ³»½Ã°æ ½Ã¼ú ½Ã°£, (2) ½Ã¼úÀÚÀÇ ±³À°/ÈÆ·ÃÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. µü Çϳª¸¸ µé¶ó¸é '³»½Ã°æ ½Ã¼ú ½Ã°£'ÀÔ´Ï´Ù. À§³»½Ã°æ °Ë»ç ½Ã°£Àº ÃÖ¼ÒÇÑ 5ºÐÀº µÇ¾î¾ß ÇÕ´Ï´Ù. ±×°Ô ÁúÀÔ´Ï´Ù.

¿ì¸®³ª¶ó¿¡¼­ ³»½Ã°æÀ» Á¦´ë·Î ¹è¿ì·Á¸é ¼ÒÈ­±â³»°ú fellow °úÁ¤Àº ÇʼöÀÔ´Ï´Ù. ´ëÃæ ¹è¿ö ¾ÆÁÖ Ãʺ¸ÀûÀÎ screeningÀ» ÇÏ·Á°í Çصµ 3°³¿ù full time trainingÀÌ ÇÊ¿äÇÕ´Ï´Ù. Dedicated center¿¡¼­ ¿­¼ºÀûÀÎ ¼±»ý¿¡°Ô 3°³¿ùÀº ¹è¿ö¾ß °¡Àå ±âÃÊÀûÀÎ À§³»½Ã°æÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù.


[2021-1-24] ³»½Ã°æÇÐȸ-¼ÒÈ­±âÇÐȸ °æÀÎÁöȸ ÇÕµ¿ ¿¬¼ö°­ÁÂ

»óºÎ³»½Ã°æ °ü·Ã °­ÀǸ¦ Àß µé¾ú½À´Ï´Ù. ³ª¸§´ë·Î ¿ä¾àÇÏ¿´½À´Ï´Ù. (¸¸³âÇÊ µ¿È£È¸ style·Î ÃÔ¿µ)


[2021-3-30] fast hand?

¾ó¸¶ Àü ¾î¶² Áú¹®À» ¹Þ°í ¾îÀÌ°¡ ¾ø¾î¼­ 5ºÐ °Ë»ç½Ã°£À» °­Á¶ÇÏ´Â ´äº¯À» Çß½À´Ï´Ù.

¹è¿ï ¶§ºÎÅÍ Á¦´ë·Î ¹è¿ì°í, ¹Ù¸£°Ô ³»½Ã°æ ÇÒ ¼ö ÀÖ´Â Á¦´ë·Î µÈ ȯ°æÀ» ¸¸µé°í, Á¦´ë·Î ÇÏ°í ÀÖ´ÂÁö monitoring ÇÏ´Â °Í... ÀÌ ¸ðµç °ÍÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¾ÈŸ±õ½À´Ï´Ù. Àú¼ö°¡ ȯ°æÀÌ Áö°ã½À´Ï´Ù.


[2021-7-7. ¾Öµ¶ÀÚ ÆíÁö]

ÀÌÁØÇà ±³¼ö´Ô ¾È³çÇϽʴϱî?

ÀüÀÓÀÇ ½ÃÀýºÎÅÍ ¿ÀÇÁ¶óÀÎ °­ÀÇ¿Í ¿£µµÅõµ¥ÀÌ Àß »ìÆ캸°í ÀÖ´Â ¼ÒÈ­±â³»°ú ÀÇ»çÀÔ´Ï´Ù. ´Ù¸§ÀÌ ¾Æ´Ï¶ó ¾ç½É»ó ´ä´äÇؼ­ »ó´ã(?), Çϼҿ¬ µå·Áº¾´Ï´Ù. ÇöÀç Á¦°¡ ±Ù¹«ÇÏ°í ÀÖ´Â º´¿øÀº ...... ¼ÒÈ­±â³»°ú ÀÇ»ç´Â Àú È¥ÀÚÀÌ°í, ´Ù¸¥ 1¸íÀº °¡Á¤ÀÇÇаú ¼±»ý´Ô, ±×¸®°í 2ºÐÀÇ ½ÅÀå³»°ú ¼±»ý´ÔÀÌ °è½ÃÁö¿ä. ´ç¿¬È÷ ³»°ú °ËÁø³»½Ã°æ ´ã´çÀº Àú¿Í °¡Á¤ÀÇÇаú ¼±»ý´ÔÀÔ´Ï´Ù.

³»½Ã°æ±â°è´Â Olympus CV190(3´ë), H170 (4´ë)series¸¦ ¾²°í Àִµ¥... ³»½Ã°æ ³¡ÀÇ bendingÀÌ Àß µÇÁö ¾Ê½À´Ï´Ù. ÃÖ´ë·Î upÀ» °É¾îµµ 160~170µµ Á¤µµ ¹Û¿¡ ¾ÈµÇ°í, ¸Å´º¾óó·³ 210µµ´Â Ä¿³ç 180µµµµ ¾È ³ª¿É´Ï´Ù. ³»½Ã°æ ´ã´ç °£È£»çºÐ²² ¸»À» Çߴµ¥, ¿Ã¸²Çª½º¿¡¼­ ¿Í¼­ ºÁÁá´Âµ¥ ³»½Ã°æÀÌ ¿À·¡ µÇ¼­(³°¾Æ¼­) ±×·±°Å¶ó°í...¼ÓÀÇ wire¸¦ ´õ Á˾îÁÙ¼ö´Â Àִµ¥, ¾ó¸¶ ¸ø°¡¼­ ´Ù½Ã Ç®¸±°Å¶õ ¼Ò¸®¸¦ µé¾ú´ä´Ï´Ù. º´¿øÃø¿¡ ¸»Àº ÇØ ³õ¾Ò´Âµ¥, (´ç¿¬È÷ Covid-19·Î ÀÎÇÏ¿© º´¿ø»çÁ¤ÀÌ ¾È ÁÁ¾ÆÁ®¼­) ±³Ã¼³ª ½ÅÇ°±¸ÀÔÀº Èûµç »óȲÀÔ´Ï´Ù. Áö±ÝÀº ¾ÆÁ÷ °ËÁø ºñ¼ö±â¶ó¼­ ÇÏ·ç¿¡ 10¸íÁ¤µµÀÇ È¯ÀÚºÐÀ» À§³»½Ã°æ °Ë»ç¸¦ Çϴµ¥... ¾ÕÀ¸·Î ´Ù°¡¿Ã ¼º¼ö±â¶§´Â ¾îÂîÇؾßÇÒÁö... ÃÖ´ëÇÑ upÀ» Çصµ bendingÀÌ Á¦´ë·Î ¾ÈµÇ´Ï cardia ºÎÀ§¸¦ °üÂûÇϱⰡ ¸Å¿ì Èûµì´Ï´Ù. StomachÀÇ angleºÎºÐÀÌ¾ß ¾î¶»°Ôµç Á¶ÀÛÇؼ­ °Ü¿ì°Ü¿ì Âï°í ÀÖÁö¸¸, cardia ºÎÀ§´Â (sample »çÁøÀ» º¸½Ã¸é ¾Æ½Ã°ÚÁö¸¸) ÁøÂ¥·Î ¾î¶»°Ô ½Ãµµ¸¦ Çغ¸¾Æµµ Àß ¾Èº¸ÀÔ´Ï´Ù. ¼±»ý´Ô²²¼­´Â ÁÁÀº ¹æ¹ýÀÌ ÀÖÀ¸½ÅÁö¿ä?

Ç×»ó ¼±»ý´Ô²²¼­ °­Á¶ÇϽô ´ë·Î ºü¸¥ ³»½Ã°æº¸´Ù´Â ¹Ù¸¥ ³»½Ã°æÀ» Ãß±¸ÇÏ°í Àִµ¥... ¾ç½É»ó ´ä´äÇÕ´Ï´Ù. ³ª´Â Àß º¸°í ½ÍÀºµ¥, (ȸ»çÅýÃ)°¡ ¾È ÁÁ¾Æ¼­ Àß °üÂû ¸øÇÏ´Â... 2021³âµµ¿¡ ¸ð À¯¸í °ËÁø±â°ü¿¡ ±Ù¹«ÇÏ¿´À» ¶§¿¡µµ ¿ÀÀü 1session¿¡¸¸ À§³»½Ã°æ 50°³, 60°³¾¿(1Àδç 1~2ºÐ! ³»½Ã°æ°üÂû½Ã°£ÀÌ µÇ´õ±º¿ä...) ÇÏ¿©¼­ ¹Ù¸¥ ³»½Ã°æº¸´Ù´Â ºü¸¥ ³»½Ã°æÀ» Çß¾ú´Âµ¥, µµÀúÈ÷ ÀÌ°Ç ¾Æ´Ï¶ó°í »ý°¢ÇÏ¿© ÀÌÁ÷ÇÑ º´¿øÀÌ ÀÌ·¸½À´Ï´Ù... º´¿øÃøÀº ¾îµð±îÁö³ª Á¤Çü/½Å°æ¿Ü°ú°¡ ÁÖ·ÂÀÌ µÇ¾î ¼öÀÍÀ» ´ã´çÇÏ°í, ³»°ú´Â ±×Àú º´¿ø ±Ô¸ð¿¡ ¸Â°Ô ²Ù¸ç³õÀº °ÍÀÌ¶ó¼­ ³»½Ã°æ½Çµµ ¸¹ÀÌ ºÎÁ·ÇÕ´Ï´Ù. ³»½Ã°æ½Ç ´ã´ç °£È£»çµµ 4¸í ¹Û¿¡ ¾ÈµÇ°í, ¾Æ¹«Æ° ¹º°¡ ¾î¼³ÇÅ´Ï´Ù.

ÀÌ´ë·Î ¾ç½É¿¡ °¡Ã¥À» ¹Þ¾Æ°¡¸é¼­ ³»½Ã°æÀ» ÇؾßÇϴ°ÍÀÎÁö, ¾Æ´Ï¸é Ÿ º´¿øÀ¸·ÎÀÇ ÀÌÁ÷À» °í·ÁÇؾßÇÏ´ÂÁö...(ÇöÀçµµ, ¼öµµ±Ç¿¡ ÀÖ´Â 2Â÷º´¿ø±Þ º´¿øµµ ¾Ë¾Æº¸°í ÀÖ½À´Ï´Ù.) ¼ÖÁ÷È÷ ´äÀÌ ¾ø´Â ¹®Á¦À̱ä ÇÏÁö¸¸, ±×·¡µµ ´ä´äÇؼ­ Çϼҿ¬ µå·Áº¾´Ï´Ù. ¾ÕÀ¸·Îµµ ¼±»ý´ÔÀÇ °­ÀÇ ¹× endotoday ÀÚÁÖ Ã£µµ·Ï ÇÏ°Ú½À´Ï´Ù. ÀоîÁּż­ °¨»çÇÕ´Ï´Ù.

[2021-7-7. ÀÌÁØÇà ´äº¯]

¿¹. ´©±¸³ª °í¹ÎÇÏ´Â ¿ì¸®³ª¶ó ÀÇ·áÀÇ Çö½ÇÀÔ´Ï´Ù. ¹ÚÁ¤Èñ µ¶Àç ¶§ ½ÃÀÛµÈ Àú°¡ °øÂ¥ ¼±½É¼º ÀÇ·á°¡ Á¤±ÇÀÌ °¥·Áµµ È£ÀüµÇ±â´Â Ä¿³ç Á¡Â÷ ¾ÇÈ­µÇ´Â »óȲÀÔ´Ï´Ù. ±×¿¡ ´õÇÏ¿© ÀÇ·á ÀÚº»°¡µéÀÌ °ÇÁø ÂÊ¿¡ Æ÷ÁøÇÏ¿© ±¹¹ÎÀÇ ÇǸ¦ »¡°í ÀÖ½À´Ï´Ù. ¿©·¯ ÈĹè ÀÇ»çµéÀÌ ÆíÇÏ°Ô ÀÏÇÒ ¼ö ÀÖ´Â ¿©°ÇÀ» ¸¸µéÁö ¸øÇØ Á˼ÛÇÕ´Ï´Ù. ÀÌÁØÇà

[2023-9-23. KSGE webinar review]


[References]

1) EndoTODAY À§³»½Ã°æ Áú°ü¸®, ÁúÁöÇ¥

2) EndoTODAY ´ëÀå³»½Ã°æ Áú°ü¸®, ÁúÁöÇ¥

3) EndoTODAY Colonoscopy withdrawal time - 6 minutes issue

4) EndoTODAY ³»½Ã°æ ¼Óµµ - ºü¸¥ ³»½Ã°æº¸´Ù ¹Ù¸¥ ³»½Ã°æ.

5) [2018-5-4. ¸ÞµðÆijª ´º½º] ³»½Ã°æ °Ë»ç ±ÞÁõ¡¦ ³»½Ã°æ½Ç ÀûÁ¤¼ºÆò°¡ ÁøÇàµÈ´Ù

Áö³­ÇØ ¿ä¾ç±Þ¿©ºñ¿ë û±¸°ÇÀ» º¸¸é, »óºÎ¼ÒÈ­±â³»½Ã°æÀº ¾à 344¸¸°Ç, ´ëÀå³»½Ã°æÀº ¾à 211¸¸°Ç¿¡ ´ÞÇß´Ù.

±¹¹Î°Ç°­º¸Çè°ø´Ü °Ç°­°ËÁø Åë°è¿¬º¸¿¡ µû¸£¸é, À§³»½Ã°æÀº 2013³â 472¸¸ 9,407¸í¿¡¼­ 2016³â 604¸¸ 8,812¸íÀ¸·Î 27.9% Áõ°¡Çß´Ù. ´ëÀå³»½Ã°æµµ 2013³â 10¸¸ 3,547¸í¿¡¼­ 2016³â 11¸¸ 7,143¸íÀ¸·Î 13.1% Áõ°¡Çß´Ù.

6) [2018-5-31. µ¥Àϸ®¸Þµð] ³»³â 1¿ù °­È­µÈ 'CT¡¤MRI Ç°Áú°ü¸®±âÁØ' Àû¿ë - (ÀÌÁØÇà ñÉ) ¿µ»óÀÇÇаú ¿µ¿ªÀÇ image quality¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. °ð ³»½Ã°æ image quality¿¡ ´ëÇؼ­µµ ´«±æÀÌ °¡°ÚÁö¿ä. ÈÄÁø ³»½Ã°æÀº »¡¸® Æó±âÇØ¾ß ÇÒ ³¯ÀÌ ¿Ã °Í °°½À´Ï´Ù.

7) ¾î¶² Facebook posting (2021-11)

8) Post-Endoscopy Upper Gastrointestinal Cancers Gastroenterology 2022;162:1123-1135.

9) [2023-5-8. Çѱ¹°æÁ¦TV] À§³»½Ã°æ ¹Þ¾Ò´Âµ¥ À§¾Ï?¡¦"Àǻ簡 3ºÐ ÀÌ»ó °üÂûÇؾß"

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.